WO2002096888A1 - Cdk inhibitorische pyrimidine, deren herstellung und verwendung als arzneimittel - Google Patents

Cdk inhibitorische pyrimidine, deren herstellung und verwendung als arzneimittel Download PDF

Info

Publication number
WO2002096888A1
WO2002096888A1 PCT/EP2002/005669 EP0205669W WO02096888A1 WO 2002096888 A1 WO2002096888 A1 WO 2002096888A1 EP 0205669 W EP0205669 W EP 0205669W WO 02096888 A1 WO02096888 A1 WO 02096888A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
cycloalkyl
alkoxy
group
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2002/005669
Other languages
German (de)
English (en)
French (fr)
Inventor
Thomas Brumby
Rolf Jautelat
Olaf Prien
Martina SCHÄFER
Gerhard Siemeister
Ulrich LÜCKING
Christoph Huwe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10127581A external-priority patent/DE10127581A1/de
Priority claimed from DE10212098A external-priority patent/DE10212098A1/de
Priority to IL15912002A priority Critical patent/IL159120A0/xx
Priority to EP02738100A priority patent/EP1392662B1/de
Priority to UA20031212505A priority patent/UA78208C2/uk
Priority to KR1020037015597A priority patent/KR100874791B1/ko
Priority to CA002449118A priority patent/CA2449118A1/en
Priority to YUP-947/03A priority patent/RS94703A/sr
Priority to AU2002312933A priority patent/AU2002312933B2/en
Priority to NZ529654A priority patent/NZ529654A/en
Application filed by Schering AG filed Critical Schering AG
Priority to JP2003500067A priority patent/JP4291135B2/ja
Priority to HR20031081A priority patent/HRP20031081A2/hr
Priority to MEP-134/08A priority patent/MEP13408A/xx
Priority to BR0209774-5A priority patent/BR0209774A/pt
Priority to DE50213202T priority patent/DE50213202D1/de
Priority to MXPA03010810A priority patent/MXPA03010810A/es
Publication of WO2002096888A1 publication Critical patent/WO2002096888A1/de
Priority to NO20035298A priority patent/NO327129B1/no
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3

Definitions

  • CDK inhibitory pyrimidines their production and use as medicines
  • the present invention relates to pyrimidine derivatives, their preparation and their use as a medicament for the treatment of various diseases.
  • CDKs cyclin-dependent kinase
  • Selective inhibitors of CDKs can be used to treat cancer or other diseases that cause cell proliferation disorders.
  • Pyrimidines and analogs have already been described as active ingredients, for example the 2-anilino-pyrimidines as fungicides (DE 4029650) or substituted pyrimidine derivatives for the treatment of neurological or neurodegenerative diseases (WO 99/19305).
  • pyrimidine derivatives are described as CDK inhibitors, for example bis (anilino) pyrimidine derivatives (WO 00/12486), 2-amino-4-substituted pyrimidines (WO 01/14375), purines (WO 99/02162), 5-cyano- Pyrimidines (WO 02/04429), anilinopyrimidines (WO 00/12486) and 2-hydroxy-3-N, N-dimethylaminopropoxy-pyrimidines (WO 00/39101).
  • bis (anilino) pyrimidine derivatives WO 00/12486
  • 2-amino-4-substituted pyrimidines WO 01/14375
  • purines WO 99/02162
  • 5-cyano- Pyrimidines WO 02/04429
  • anilinopyrimidines WO 00/12486
  • 2-hydroxy-3-N, N-dimethylaminopropoxy-pyrimidines WO 00/39101
  • the object of the present invention is to provide compounds which have better properties than the inhibitors already known.
  • the substances described here are more effective because they already inhibit in the nanomolar range and thus from other known CDK inhibitors such as e.g. Olomoucin and Roscovitin are to be distinguished.
  • R 1 for hydrogen, halogen, Ci-C ⁇ -alkyl, nitro or for the
  • Cycloalkyl is one or more, identical or different with hydroxy, halogen, -CC 6 -alkoxy, d-C ⁇ -alkylthio, amino, cyano, dC 6 -alkyl, -NH- (CH 2 ) n -C 3 -C ⁇ 0 - cycloalkyl, C 3 -C ⁇ 0 cycloalkyl, d-Ce-hydroxyalkyl, C 2 -C 6 -
  • X 1 0 cycloalkyl which may be mono- or poly-substituted, identically or differently with a heteroaromatic oxygen or for the group -NH-, -N (dC 3 alkyl) or -OC 3 -C stands or X and R 2 together form a C 3 -C 10 cycloalkyl ring which may optionally contain one or more heteroatoms and may optionally be substituted one or more times with hydroxy, dC 6 alkyl, Ci-C ⁇ -alkoxy or halogen,
  • a and B are each independently of one another for hydrogen, hydroxyl, dC 3 -alkyl, Ci-Ce-alkoxy or for the group -SR 7 , - S (O) R 7 , -SO 2 R 7 , -NHSO 2 R 7 , - CH (OH) R 7 , -CR 7 (OH) -R 7 , dC 6 -alkylP (O) OR 3 OR 4 , -
  • a and B together form a C 3 -C 10 cycloalkyl ring which may be formed by one or more nitrogen,
  • Groups in the ring can be interrupted and / or one or more possible double bonds can optionally be contained in the ring and the C3-C ⁇ o-cycloalkyl ring optionally one or more times, identically or differently, with hydroxyl, halogen, Ci-Ce
  • R 6 represents a heteroaryl or C 3 -C ⁇ o-cycloalkyl ring, the ring having the meaning given above, R 7 represents halogen, hydroxy, phenyl, dC 6 alkyl, C 2 -C 6 alkenyl,
  • Alkoxy can be substituted, substituted -CC-alkyl, C 2 - do-alkenyl,
  • Alkoxy, halo -CC 6 alkyl, halo-DC 6 -alkoxy may be substituted, R 8 , R 9 and R 10 each independently of one another for hydrogen, hydroxy, Ci-do-alkyl, C 2 -C 0 -alkenyl , C 2 -C ⁇ 0 alkynyl, C 3 -C10-
  • Heteroaryl itself may be substituted one or more times, identically or differently, with halogen, hydroxy, C 6 -C 6 alkyl, C 1 -C alkoxy, or with the group -CF 3 or -OCF3, and the ring of C 3 - d 0 -cycloalkyls and the C 1 -C 8 -alkyl, optionally with one or more nitrogen,
  • Alkyl is in each case a straight-chain or branched alkyl radical, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec. Butyl, tert. Butyl, pentyl, isopentyl, hexyl, heptyl, octyl, nonyl and decyl.
  • alkyl radical such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec. Butyl, tert. Butyl, pentyl, isopentyl, hexyl, heptyl, octyl, nonyl and decyl.
  • Alkoxy is in each case a straight-chain or branched alkoxy radical, such as, for example, methyloxy, ethyloxy, propyloxy, isopropyloxy, butyloxy,
  • Alkylthio is in each case a straight-chain or branched alkylthio radical, such as, for example, methylthio, ethylthio, propylthio, isopropylthio, butylthio, isobutylthio, sec. To understand butylthio, tert-butylthio, pentylthio, isopentylthio or hexylthio.
  • Cycloalkyl is generally understood to mean monocyclic alkyl rings such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl or cyclodecyl, but also bicyclic rings or tricyclic rings such as, for example, norbomyl, adamantanyl, etc.
  • ring systems in which one or more possible double bonds may be present in the ring are understood to mean, for example, cycloalkenyls such as cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, it being possible for the linkage to take place both on the double bond and on the single bonds ,
  • Halogen is to be understood as fluorine, chlorine, bromine or iodine.
  • alkenyl substituents are in each case straight-chain or branched, which means, for example, the following radicals: vinyl, propen-1-yl, propen-2-yl, but-1-en-1-yl, but-1-en-2-yl , But-2-en-1-yl, but-2-en-2-yl, 2-methyl-prop-2-en-1-yl, 2-methyl-prop-1-en-1-yl, but -1-en-3-yl, ethynyl, prop-1-in-1-yl, but-1-in-1-yl, but-2-in-1-yl, but-3-en-1-yl , Allyl.
  • Alkynyl is in each case to be understood as a straight-chain or branched alkynyl radical which contains 2-6, preferably 2-4, carbon atoms.
  • the following radicals may be mentioned, for example: acetylene, propin-1-yl, propin-3-yl, but-1-in-1-yl, but-1-in-4-yl, but-2-in-1-yl , But-1-in-3-yl, etc.
  • the aryl radical contains 3 to 12 carbon atoms and can be benzo-fused.
  • Examples include: cyclopropenyl, cyclopentadienyl, phenyl, tropyl, cyclooctadienyl, indenyl, naphthyl, azulenyl, biphenyl, fluorenyl, anthracenyl etc.
  • the heteroaryl radical each comprises 3-16 ring atoms and can contain one or more identical or different heteroatoms, such as oxygen, nitrogen or sulfur in the ring, instead of carbon, and can be mono-, bi- or tricyclic, and can additionally be benzo-fused in each case ,
  • Examples include:
  • Heterocycloalkyl stands for an alkyl ring comprising 3 to 12 carbon atoms, which instead of the carbon has one or more, identical or different, heteroatoms, such as e.g. B. contains oxygen, sulfur or nitrogen. As heterocycloalkyl such. B.
  • oxiranyl oxethanyl, aziridinyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl, dioxolanyl, imidazolidinyl, pyrazolidinyl, dioxanyl, piperidinyl, morpholinyl, dithianyl, thiomorpholinyl, piperazinyl, trithianyl etc., quinuclidinyl
  • Heterocycloalkenyl represents an alkyl ring comprising 3 to 12 carbon atoms, which instead of the carbon has one or more, the same or various heteroatoms, such as B. contains oxygen, sulfur or nitrogen, and which is partially saturated.
  • heterocycloalkenyls such as: Pyran, Thiin, Dihydroazet, etc.
  • the physiologically tolerable salts of organic and inorganic bases are suitable as salts, such as the readily soluble alkali and alkaline earth metal salts and N-methylglucamine, dimethylglucamine, ethylglucamine, lysine, 1,6-hexadiamine , Ethanolamine, glucosamine, sarcosine, serinol, tris-hydroxy-methyl-amino-methane, aminopropanediol, Sovak base, 1-amino-2,3,4-butanetriol.
  • physiologically compatible salts of organic and inorganic acids such as hydrochloric acid, sulfuric acid, phosphoric acid, citric acid, tartaric acid and others are suitable.
  • R represents hydrogen, halogen, -CC 6 alkyl, nitro or the group -COR 5 , -OCF 3 , - (CH 2 ) n R 5 , -S-CF 3 or -SO 2 CF 3 , R 2 for Ci-Cio-alkyl, C 2 -C ⁇ 0 -alkenyl, C 2 -C ⁇ 0 -alkynyl or C 3 -C ⁇ 0 -
  • X is oxygen or the group -NH-, -N (dC 3 -alkyl) or -OC 3 -C ⁇ o -cycloalkyl which can be substituted one or more times, identically or differently, with a heteroaromatic, or X and R 2 together form a C 3 -C 0 cycloalkyl ring which can optionally contain one or more heteroatoms and optionally one or more times with hydroxy,
  • C 1 -C 6 alkyl, C 1 -C 6 alkoxy or halo may be substituted
  • a and B are each independently of one another for hydrogen, hydroxy, -CC 3 -alkyl, dC 6 -alkoxy or for the group -S-CH 3 , -S0 2 - C 2 H 4 -OH, -CO-CH 3 , - S-CHF 2 , -S- (CH 2 ) n CH (OH) CH 2 N- R 3 R 4 , -CH 2 P (O) OR 3 OR 4 , -S-CF 3 , -SO-CH3, - SO 2 CF 3 , - SO 2 - (CH 2 ) n -NR 3 R 4 , -SO 2 -NR 3 R 4 , -SO 2 R 7 , -CH- (OH) -CH 3 or for
  • a and B together form a group
  • R 4 are each independently hydrogen, phenyl, benzyloxy, C ⁇ -C ⁇ 2 alkyl, Ci-Ce alkoxy, C 2 -C 4 alkenyloxy, C 3 -C 6 -cycloalkyl, hydroxy, hydroxy-C ⁇ -C 6 alkyl, dihydroxy-Ci-C ⁇ -alkyl, heteroaryl, heterocyclo-C 3 -C ⁇ 0 alkyl, heteroaryl-C ⁇ -C3 alkyl optionally substituted by cyano C 3 -C 6 cycloalkyl, C ⁇ -C 3 alkyl, or optionally substituted one or more times, identically or differently with phenyl, pyridyl, phenyloxy, C 3 -C 6 cycloalkyl, C C ⁇ - alkyl or Ci-Ce-alkoxy, C ⁇ -C 6 -alkyl, wherein the phenyl itself can be substituted one or more times, identically or differently, with
  • R fc for hydroxy, phenyl, Ci-Ce-alkyl, C 3 -C 6 cycloalkyl,
  • R 7 for halogen, hydroxy, phenyl, dC 6 alkyl, -C 2 H 4 OH, -NR 3 R 4 , or the group stands,
  • R 10 each independently of one another for hydrogen, hydroxy
  • Ci-Ce-alkyl C 3 -C 6 -cyclolkyl or for the group
  • n stands for 0-6, mean, and their isomers, enantiomers, diastereomers and salts.
  • R 1 is hydrogen, halogen, C 1 -C 3 -alkyl or the group
  • R 2 is -CH (CH 3 ) - (CH 2 ) n -R 5 , -CH- (CH 2 OH) 2 , - (CH 2 ) n R 7 , -CH (C 3 H 7 ) - (CH 2 ) n -R5, -CH (C 2 H 5 ) - (CH 2 ) n -R 5 , -CH 2 -CN, -CH (CH 3 ) COCH 3 , -CH (CH 3 ) -C (OH) (CH 3 ) 2 , -CH (CH (OH) CH 3 ) OCH 3 , -CH (C 2 H 5 ) CO-R 5 , C 2 -C 4 alkynyl , - (CH 2 ) n -COR 5 , - (CH 2 ) n -CO-C ⁇ -C 6 alkyl, - (CH 2 ) n -C (OH)
  • a and B are each independently of one another for hydrogen, hydroxyl, dC 3 -alkyl, Ci-Ce-alkoxy or for the group -S-CH 3 , -SO 2 -C 2 H 4 -OH, -CO-CH3, -S- CHF 2 , -S- (CH 2 ) n CH (OH) CH 2 NR 3 R 4 , -CH 2 PO (OC 2 H 5 ) 2 , -S-CF 3 , -SO-CH 3 , -SO 2 CF 3 , -SO 2 - (CH 2 ) n -NR 3 R 4 , -SO 2 -NR 3 R 4 ,
  • R 3 and R 4 are each independently hydrogen, phenyl, benzyloxy, C ⁇ -d 2 -alkyl, C 6 alkoxy, C 2 -C alkenyloxy, C 3 -C 6 -cycloalkyl, hydroxy, hydroxyC -dC 6 alkyl, dihydroxy-C ⁇ -C 6 -alkyl, heteroaryl, heterocyclo-C 3 -C ⁇ 0 alkyl, heteroaryl-C ⁇ -C3 alkyl optionally substituted by cyano C 3 -C 6 cycloalkyl C ⁇ - C 3 alkyl, or optionally substituted one or more times, identically or differently with phenyl, pyridyl, phenyloxy, C 3 -C 6 cycloalkyl, Ci-Ce alkyl or C 1 -C 6 alkoxy substituted Ci-Ce-alkyl , where the phenyl itself can be substituted one or more times, identically or differently, with hal
  • R b for hydroxy, phenyl, Ci-Ce-alkyl, C 3 -C 6 cycloalkyl,
  • R 7 for halogen, hydroxy, phenyl, Ci-Ce-alkyl, - (CH 2 ) n OH,
  • R 10 for hydrogen, hydroxy, -CC 6 alkyl or for the group
  • n stand for 0-6, mean, and their isomers, diastereoisomers, enantiomers and salts.
  • the compounds according to the invention essentially inhibit cyclin-dependent kinases, whereupon their action, for example, against cancer, such as solid tumors and leukemia, autoimmune diseases such as psoriasis,
  • the eukaryotic cell division cycle ensures the duplication of the genome and its distribution to the daughter cells by going through a coordinated and regulated sequence of events.
  • the cell cycle is divided into four successive phases: the G1 phase represents the time before DNA replication in which the cell grows and is susceptible to external stimuli.
  • the S phase the cell replicates its DNA
  • the G2 phase it prepares to enter mitosis.
  • the mitosis (M phase) the replicated DNA is separated and the cells are divided.
  • CDKs The cyclin-dependent kinases
  • CDKs a family of serine / threonine kinases, the members of which require the binding of a cyclin (Cyc) as a regulatory subunit to activate them, drive the cell through the cell cycle.
  • CDK / Cyc pairs are active in the different phases of the cell cycle.
  • CDK / Cyc pairs which are important for the basic function of the cell cycle are, for example, CDK4 (6) / CycD, CDK2 / CycE, CDK2 / CycA, CDK1 / CycA and CDK1 / CycB.
  • CDK5 Some members of the CDK enzyme family have a regulatory function by influencing the activity of the aforementioned cell cycle CDKs, while other members of the CDK enzyme family have not yet been assigned a specific function.
  • CDK5 is characterized by the fact that it has an atypical regulatory subunit that differs from the cyclin (p35) and that its activity is highest in the brain.
  • the entry into the cell cycle and the passage through the "restriction point", which marks the independence of a cell from further growth signals for the completion of the started cell division, are controlled by the activity of the CDK4 (6) / CycD and CDK2 / CycE complexes.
  • the main substrate of these CDK complexes is the retinoblastoma protein (Rb), the product of the retinoblastoma tumor suppressor gene.
  • Rb is a transcriptional co-repressor protein.
  • Rb binds and inactivates transcription factors of the E2F type, and forms transcriptional repressor complexes with histone deacetylases (HDAC) (Zhang HS et al. (2000).
  • HDAC histone deacetylases
  • the activity of the CDK2 / CycE and CDK2 / CycA complexes is necessary, e.g. B. the activity of the transcription factors of the E2F type is switched off by means of phosphorylation by CDK2 / CycA as soon as the cells have entered the S phase.
  • the CDK1 in complex with CycA or CycB controls the entry and the passage through phases G2 and M (Fig. 1).
  • the cycle is strictly regulated and controlled.
  • the enzymes that are necessary for progression through the cycle must be activated at the right time and also switched off again as soon as the corresponding phase has been completed.
  • Corresponding control points arrest the progression through the cell cycle if DNA damage is detected, or DNA replication, or the construction of the spindle apparatus has not yet ended.
  • the activity of the CDKs is directly controlled by various mechanisms, such as synthesis and degradation of the cyclines, complexation of the CDKs with the corresponding cyclins, phosphorylation and dephosphorylation of regulatory threonine and tyrosine residues, and the binding of natural inhibitory proteins.
  • CDK / Cyc complexes The regulation of the activity of the CDK / Cyc complexes by two families of natural CDK inhibitor proteins (CKIs), the protein products of the p21 gene family (p21, p27, p57) and the p16 gene family (p15, p16, p18, p19) is very important.
  • CKIs CDK inhibitor proteins
  • Members of the p21 family bind to cyclin complexes of CDKs 1, 2,4,6, but only inhibit complexes that contain CDK1 or CDK2.
  • Members of the p16 family are specific inhibitors of the CDK4 and CDK6 complexes.
  • the level of the control point regulation lies above this complex direct regulation of the activity of the CDKs.
  • Control points allow the cell to follow the orderly progress of the individual phases during the cell cycle. The most important control points are at the transition from G1 to S and from G2 to M.
  • the G1 control point ensures that the cell does not begin DNA synthesis if it is not properly nourished, interacts correctly with other cells or the substrate, and their DNA is intact.
  • the G2 / M control point ensures the complete replication of the DNA and the build-up of the mitotic spindle before the cell enters mitosis.
  • the G1 control point is activated by the gene product of the p53 tumor suppressor gene.
  • a second branch of the G1 checkpoint includes the
  • the loss of regulation of the cell cycle and the loss of the function of the control points are characteristics of tumor cells.
  • the CDK-Rb signaling pathway is affected by mutations in over 90% of human tumor cells. These mutations, which ultimately lead to inactivating phosphorylation of the RB, include overexpression of D and E cyclins by gene amplification or chromosomal translocations, inactivating mutations or deletions of CDK inhibitors of the p16 type, and increased (p27) or reduced (CycD ) Protein breakdown.
  • p53 which is essential for the G1 and G2 / M control points, is the most frequently mutated gene in human tumors (approx. 50%). In tumor cells that express p53 without a mutation, it is often inactivated due to a greatly increased protein degradation. Similarly, the genes of other proteins necessary for the function of the control points are affected by mutations, for example ATM (inactivating mutations) or cdc25 phosphatases (overexpression).
  • CDK2 / Cyc complexes occupy a crucial position during cell cycle progression: (1) Both dominant-negative forms of CDK2, as well as the transcriptional repression of CDK2 expression by anti-sense oligonucleotides, stop cell cycle progression. (2) Inactivation of the CycA gene in mice is lethal. (3) Disruption of the function of the CDK2 / CycA complex in cells by means of cell-permeable peptides led to tumor cell-selective apoptosis (Chen YNP et al. (1999). Selective killing of transformed cells by cyclin / cyclin-dependent kinase 2 antagonists. Proc. Natl. Acad. Be. USA 96, 4325-4329).
  • Changes in cell cycle control do not only play a role in cancer.
  • the cell cycle is activated by a number of viruses, both transforming and non-transforming, in order to allow the multiplication of the viruses in the host cell.
  • Incorrect entry into the cell cycle of normally post-mitotic cells is associated with various neurodegenerative diseases.
  • the mechanisms of cell cycle regulation, their changes in diseases and a variety of approaches for the development of inhibitors of cell cycle progression and especially CDKs have already been described in detail in several publications (Sielecki TM et al. (2000). Cyclin-dependent kinase inhibitors: useful targets in Cell cycle regulation. J. Med. Chem. 43, 1-18; Fry DW & Garrett MD (2000).
  • Inhibitors of cyclin-dependent kinases as therapeutic agents for the treatment of cancer Curr. Opin. Oncol. Endo. Metab Invest. Drugs 2, 40-59; Rosiania GR & Chang YT (2000). Targeting hyperproliferative disorders with cyclin dependent kinase inhibitors. Exp. Opin. Ther. Patents 10, 215-230; Meijer L. et al. (1999) Properties and potential applications of chemical inhibitors of cyclin-dependent kinases. Pharmacol. Ther. 82, 279-284; Senderowicz AM & Sausville EA (2000). Preclinical and clinical development of cyclin-dependent kinase modulators. J. Natl. Cancer Inst. 92, 376-387).
  • a pharmaceutical preparation which, in addition to the active ingredient for enteral or parenteral administration, has suitable pharmaceutical, organic or inorganic inert carrier materials, such as, for example, water, gelatin, gum arabic, lactose, starch , Magnesium stearate, talc, vegetable oils, polyalkylene glycols etc. contains.
  • the pharmaceutical preparations can be in solid form, for example as tablets, dragees, suppositories, capsules or in liquid form, for example as solutions, suspensions or emulsions. Possibly included they also auxiliaries, such as preservatives, stabilizers, wetting agents or emulsifiers; Salts to change the osmotic pressure or buffer.
  • auxiliaries such as preservatives, stabilizers, wetting agents or emulsifiers; Salts to change the osmotic pressure or buffer.
  • Injection solutions or suspensions in particular aqueous solutions of the active compounds in polyhydroxyethoxylated castor oil, are particularly suitable for parenteral use.
  • Surfactant auxiliaries such as salts of bile acids or animal or vegetable phospholipids, but also mixtures thereof and liposomes or their components can also be used as carrier systems.
  • Tablets, coated tablets or capsules with talc and / or hydrocarbon carriers or binders, such as lactose, corn or potato starch, are particularly suitable for oral use. It can also be used in liquid form, for example as juice, to which a sweetener may be added.
  • enteral, parenteral and oral applications are also the subject of the present invention.
  • the dosage of the active ingredients can vary depending on the route of administration, age and weight of the patient, type and severity of the disease to be treated and similar factors.
  • the daily dose is 0.5-1000 mg, preferably 50-200 mg, and the dose can be given as a single dose to be administered once or divided into 2 or more daily doses.
  • the present invention also relates to the use of
  • autoimmune diseases for the manufacture of a medicament for the treatment of cancer, autoimmune diseases, cardiovascular diseases, chemotherapy-induced alopecia and mucositis, infectious diseases, nephrological diseases, chronic and acute neurodegenerative diseases and viral infections, with solid tumors and leukemia under cancer, psoriasis, alopecia and multiple sclerosis under autoimmune diseases, stenoses, arteriosclerosis and restenoses under cardiovascular diseases, and unicellular parasites under infectious diseases, among nephrological diseases glomerulonephritis, under chronic neurodegenerative diseases Huntington 's disease, amyotrophic lateral sclerosis, Parkinson' s disease, AIDS dementia and Alzheimer 's disease, under acute neurodegenerative diseases ischemia of the brain and
  • Neurotraumata, and viral infections include cytomegalus infections, herpes, hepatitis B or C, and HIV diseases.
  • the present invention also relates to medicaments for the treatment of the diseases listed above, which have at least one
  • the compounds of general formula I according to the invention include excellent inhibitors of cyclin-dependent kinases, such as CDK1, CDK2, CDK3, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, and glycogen synthase kinase (GSK-3ß).
  • cyclin-dependent kinases such as CDK1, CDK2, CDK3, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9
  • GSK-3ß glycogen synthase kinase
  • the isomer mixtures can be converted into the enantiomers or E / Z by conventional methods such as, for example, crystallization, chromatography or salt formation.
  • the salts are prepared in a conventional manner by adding a solution to the
  • Substance 40 is produced analogously to example 2 Chromatography: H / EA 1: 30.5% TEA
  • 0.2 ml of a 0.5 M 4-phenylpiperazine solution in DMPU is added to a solution of 19 mg (0.05 mM) of substance 51 in N, N'-dimethylpropylurea (DMPU).
  • the reaction mixture is kept at a temperature of 80 ° C. for 18 hours.
  • 3.5 ml of tertiary butyl methyl ether are added and the organic phase is extracted 5 times with 1.5 ml of H 2 O and then evaporated in vacuo.
  • Example No. 122 202 mg (0.60 mmol) of the compound Example No. 122 are mixed with 1 ml of water and 0.2 g (1.2 mmol) of bromine and stirred at room temperature. After 24 hours, 0.2 g (1.2 mmol) of bromine are again added and the mixture is stirred at room temperature for a further 24 hours. The solvent is Evaporated under vacuum and the remaining residue was purified by chromatography (Flashmaster II, DCM / MeOH 7: 3). 17 mg (0.04 mmol, 7%) of the product are obtained as a white solid.
  • the oxime ethers are prepared according to the following general reaction scheme:
  • R 8 and R 9 have the meanings given in the general formula I.
  • 0.2 mmol of sulfonic acid fluoride are placed in the ReaWor of a synthesizer.
  • 1.0 ml of solvent, preferably 2-butanol is added.
  • 0.2 ml (0.2 mmol) of DMAP - dissolved in a solvent, for example DMSO or 2-butanol - and 0.2 ml (0.2 mmol) of the amine, dissolved in 2-butanol, are added in succession via a pipette.
  • the reaction mixture is then stirred at 80 ° C. for 20 hours.
  • the crude product is pipetted off and the reactor is washed with 1.0 mL THF.
  • the solution of the crude product is then concentrated and purified by means of HPLC.
  • the pyrimidine sulfonic acid fluorides are prepared analogously to the preparation of the sulfonic acid amides.
  • Racemates A and B were then separated by means of chiral HPLC.
  • the 4- (diaminocyclohexyl) derivatives described below are synthesized via reductive aminations of the keto derivative described using triacetoxyborohydride (Abdel-Magid, Carson, Harris, Maryanoff, Sha, J. Org. Chem. 1996, 61, 3849).
  • the keto derivative is obtained by TPAP oxidation (Griffith, Ley, Aldrichimica Acta 1990, 23, 13) of the corresponding alcohol.
  • the following interconnections are also produced in an analogous procedure.
  • the present invention thus also relates to compounds of the general formula Ia
  • Another object of the present invention are also those compounds which fall under the property right DE 4029650 and whose action is in the fungicidal range, but which are not described as CDK inhibitors, and their use for the treatment of cancer is also not described.
  • the invention thus further relates to pharmaceutical compositions comprising a compound of general formula I in the
  • R 1 represents halogen or CC 3 alkyl
  • X represents oxygen or -NH
  • R 2 , R 3 , R 4 , R 7 and R 8 have the meanings given in the general formula I, and the isomers, diastereomers, enantiomers and salts.
  • the agents according to the invention can also be used to treat cancer, autoimmune diseases, cardiovascular diseases, chemotherapeutic-induced alopecia and mucositis, infectious diseases, nephrological diseases, chronic and acute neurodegenerative diseases and viral infections, with cancer being solid tumors and leukemia, with autoimmune diseases psoriasis, alopecia and multiple sclerosis, under cardiovascular diseases stenoses, arterioscleroses and restenoses, under infectious diseases caused by unicellular parasites, under nephrological diseases glomerulonephritis, under chronic neurodegenerative diseases Huntington's disease, amyotrophic lateral sclerosis, Parkinson's disease, AIDS dementia and Alzheimer's disease neurodegenerative diseases ischemia of the brain and neurotrauma, and among viral infections cytomegalus infections, herpes, hepatitis B o the C, and HIV diseases are used.
  • the following examples describe the biological action of the compounds according to the invention without restricting the invention to these examples.
  • CDK2 and CycE-GST fusion proteins purified from baculovirus-infected insect cells were developed by Dr. Dieter Marme, Clinic for Tumor Biology Dortmund. Histone IIIS, which was used as the kinase substrate, was purchased from Sigma.
  • CDK2 / CycE 50 ng / measuring point
  • was in assay buffer [50 mM Tris / HCl pH 8.0, 15 min at 22 ° C. in the presence of various concentrations of test substances (0 ⁇ M, as well as within the range 0.01-100 ⁇ M).
  • Cultivated human tumor cells (as indicated) were plated at a density of 5000 cells / measuring point in a 96-well multititer plate in 200 ⁇ l of the corresponding growth medium. After 24 hours, the cells of one plate (zero point plate) were stained with crystal violet (see below), while the medium of the other plates was mixed with fresh culture medium (200 ⁇ l) containing the test substances in various concentrations (0 ⁇ M and in the range 0.01 - 30 ⁇ M; the final concentration of the solvent dimethyl sulfoxide was 0.5%) were replaced. The cells were incubated for 4 days in the presence of the test substances.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/EP2002/005669 2001-05-29 2002-05-23 Cdk inhibitorische pyrimidine, deren herstellung und verwendung als arzneimittel Ceased WO2002096888A1 (de)

Priority Applications (15)

Application Number Priority Date Filing Date Title
DE50213202T DE50213202D1 (de) 2001-05-29 2002-05-23 Cdk inhibitorische pyrimidine, deren herstellung und verwendung als arzneimittel
MXPA03010810A MXPA03010810A (es) 2001-05-29 2002-05-23 Pirimidinas inhibidoras de cdk, su obtencion y su uso como medicamentos.
JP2003500067A JP4291135B2 (ja) 2001-05-29 2002-05-23 Ｃｄｋ阻害性ピリミジン、それらの製造および薬剤としての使用
UA20031212505A UA78208C2 (en) 2001-05-29 2002-05-23 Cdk inhibiting pyrimidines, production thereof and their use as medicaments
KR1020037015597A KR100874791B1 (ko) 2001-05-29 2002-05-23 Ｃｄｋ-억제 피리미딘, 그의 제조방법 및 약제로서의 용도
CA002449118A CA2449118A1 (en) 2001-05-29 2002-05-23 Cdk inhibiting pyrimidines, production thereof and their use as medicaments
YUP-947/03A RS94703A (sr) 2001-05-29 2002-05-23 Cdk-inhibirajući pirimidini, njihovo dobijanje i primena kao sredstva za lečenje
AU2002312933A AU2002312933B2 (en) 2001-05-29 2002-05-23 CDK inhibiting pyrimidines, production thereof and their use as medicaments
NZ529654A NZ529654A (en) 2001-05-29 2002-05-23 CDK inhibiting pyrimidines, production thereof and their use as medicaments
IL15912002A IL159120A0 (en) 2001-05-29 2002-05-23 Cdk inhibiting pyrimidines, production thereof and their use as medicaments
EP02738100A EP1392662B1 (de) 2001-05-29 2002-05-23 Cdk inhibitorische pyrimidine, deren herstellung und verwendung als arzneimittel
HR20031081A HRP20031081A2 (en) 2001-05-29 2002-05-23 Cdk inhibiting pyrimidines, production thereof and their use as medicaments
MEP-134/08A MEP13408A (en) 2001-05-29 2002-05-23 Cdk inhibiting pyrimidines, production thereof and their use as medicaments
BR0209774-5A BR0209774A (pt) 2001-05-29 2002-05-23 Pirimidinas inibidoras de cdk, sua preparação e aplicação como medicamento
NO20035298A NO327129B1 (no) 2001-05-29 2003-11-28 CDK-inhiberende pyrimider, farmasoytiske preparater,og deres anvendelse for fremstilling av legemidler

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10127581A DE10127581A1 (de) 2001-05-29 2001-05-29 CDK inhibitorische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
DEDE10127581.1 2001-05-29
DE10212098A DE10212098A1 (de) 2002-03-11 2002-03-11 CDK inhibitorische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
DEDE10212098.6 2002-03-11

Publications (1)

Publication Number Publication Date
WO2002096888A1 true WO2002096888A1 (de) 2002-12-05

Family

ID=26009483

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/005669 Ceased WO2002096888A1 (de) 2001-05-29 2002-05-23 Cdk inhibitorische pyrimidine, deren herstellung und verwendung als arzneimittel

Country Status (23)

Country Link
US (3) US7235561B2 (https=)
EP (1) EP1392662B1 (https=)
JP (1) JP4291135B2 (https=)
KR (1) KR100874791B1 (https=)
CN (1) CN100480242C (https=)
AR (1) AR036035A1 (https=)
AT (1) ATE420077T1 (https=)
AU (1) AU2002312933B2 (https=)
BR (1) BR0209774A (https=)
CA (1) CA2449118A1 (https=)
CO (1) CO5540316A2 (https=)
DE (1) DE50213202D1 (https=)
ES (1) ES2320204T3 (https=)
HR (1) HRP20031081A2 (https=)
IL (1) IL159120A0 (https=)
ME (1) MEP13408A (https=)
MX (1) MXPA03010810A (https=)
NO (1) NO327129B1 (https=)
NZ (1) NZ529654A (https=)
PL (1) PL367130A1 (https=)
RS (1) RS94703A (https=)
RU (1) RU2330024C2 (https=)
WO (1) WO2002096888A1 (https=)

Cited By (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003032994A3 (de) * 2001-10-17 2003-06-12 Boehringer Ingelheim Pharma 5-substituierte 4-amino-2-phenylamino-pyrimidinderivate und ihre verwendung als beta-amyloid modulatoren
WO2003055489A1 (en) * 2001-12-21 2003-07-10 Bayer Pharmaceuticals Corporation 2,4-diamino-pyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
EP1438053A1 (de) 2001-10-17 2004-07-21 Boehringer Ingelheim Pharma GmbH & Co.KG Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung
WO2004056786A3 (en) * 2002-12-20 2004-10-21 Pfizer Prod Inc Pyrimidine derivates for the treatment of abnormal cell growth
WO2005037800A1 (de) * 2003-10-16 2005-04-28 Schering Aktiengesellschaft Sulfoximinsubstituierte pyrimidine als cdk- und/oder vegf-inhibitoren, deren herstellung und verwendung als arzneimittel
WO2005016893A3 (en) * 2003-07-30 2005-06-09 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
WO2005063722A1 (en) * 2003-12-19 2005-07-14 Rigel Pharmaceuticals, Inc. Stereoisomers and stereoisomeric mixtures of 1-(2,4-pyrimidinediamino)-2-cyclopentanecarboxamide synthetic intermediates
WO2005111024A1 (en) * 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
EP1471915A4 (en) * 2002-02-01 2006-02-15 Rigel Pharmaceuticals Inc 2,4-pyrimidine-dinamine compounds and their use
WO2006034872A1 (de) * 2004-09-29 2006-04-06 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-anilinopyrimidine als zellzyklus -kinase oder rezeptortyrosin-kinase inhibitoren, deren herstellung und verwendung als arzneimittel
WO2006077428A1 (en) 2005-01-21 2006-07-27 Astex Therapeutics Limited Pharmaceutical compounds
WO2006087230A1 (de) * 2005-02-17 2006-08-24 Schering Aktiengesellschaft Verwendung von cdk ii inhibitoren zur fertilitätskontrolle
US7109335B2 (en) 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
US7109337B2 (en) 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
EP1705177A1 (en) * 2005-03-23 2006-09-27 Schering Aktiengesellschaft N-aryl-sulfoximine-substituted pyrimidines as CDK- and/or VEGF inhibitors, their production and use as pharmaceutical agents
US7145008B2 (en) 2004-05-14 2006-12-05 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
WO2007003596A1 (de) * 2005-07-01 2007-01-11 Boehringer Ingelheim International Gmbh 2,4-diamino-pyrimidine als aurora inhibitoren
JP2007501793A (ja) * 2003-08-07 2007-02-01 リゲル ファーマシューティカルズ，インコーポレイティド 抗増殖剤としての２，４−ピリミジンジアミン化合物および使用
WO2007060110A1 (en) * 2005-11-22 2007-05-31 F. Hoffmann-La Roche Ag 4-aminopyrimidine-5-thione-derivatives for the treatment of cancer
US7235562B2 (en) 2004-05-14 2007-06-26 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
EP1803723A1 (de) 2006-01-03 2007-07-04 Bayer Schering Pharma Aktiengesellschaft (2,4,9-triaza-1(2,4)-pyrimidina-3(1,3)-benzenacyclononaphan-3^4-yl)-sulfoximid derivate als selektive inhibitoren der aurora kinase zur behandlung von krebs
WO2007089445A2 (en) 2006-01-27 2007-08-09 Amgen Inc. Ang2 and vegf inhibitor combinations
WO2006133426A3 (en) * 2005-06-08 2007-11-08 Rigel Pharmaceuticals Inc Compositions and methods for inhibition of the jak pathway
EP1878726A1 (en) * 2006-07-12 2008-01-16 Bayer Schering Pharma Aktiengesellschaft Substituted sulphoximines as Tie2 inhibitors and salts thereof, pharmaceutical compositions comprising the same, methods of preparing the same and uses of the same
WO2008044041A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
WO2008044045A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
WO2008074515A1 (de) * 2006-12-20 2008-06-26 Bayer Schering Pharma Aktiengesellschaft Neuartige hetaryl-phenylendiamin-pyrimidine als proteinkinaseinhibitoren zur behandlung von krebs
WO2008077885A2 (en) 2006-12-22 2008-07-03 Boehringer Ingelheim International Gmbh 2- [(phenylamino) -pyrimidin-4ylamin0] -cyclopentane carboxamide derivatives and related compounds as inhibitors of kinases of the cell cycle for the treatment of cancer
WO2008079907A1 (en) * 2006-12-20 2008-07-03 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
DE102007010801A1 (de) 2007-03-02 2008-09-04 Bayer Cropscience Ag Diaminopyrimidine als Fungizide
US7427626B2 (en) 2003-05-16 2008-09-23 Astrazeneca Ab 2-Anilino-4-(imidazol-5-yl)-pyrimidine derivatives and their use as cdk (cdk2) inhibitors
US7442697B2 (en) 2002-03-09 2008-10-28 Astrazeneca Ab 4-imidazolyl substituted pyrimidine derivatives with CDK inhibitory activity
US7446105B2 (en) 2002-03-09 2008-11-04 Astrazeneca Ab Pyrimidine compounds
US7449458B2 (en) 2005-01-19 2008-11-11 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US7465728B2 (en) 2002-03-09 2008-12-16 Astrazeneca Ab Derivatives of 4-(imidazol-5-yl)-2-(4-sulfoanilino)pyrimidine with CDK inhibitory activity
US7485638B2 (en) 2002-03-09 2009-02-03 Astrazeneca Ab Pyrimidine compounds
US7517886B2 (en) 2002-07-29 2009-04-14 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
WO2008140421A3 (en) * 2007-05-15 2009-04-30 S Bio Pte Ltd Heterocycloalkyl substituted pyrimidine derivatives
RU2356901C2 (ru) * 2003-07-30 2009-05-27 Райджел Фармасьютикалз, Инк. Соединения 2, 4-пиримидиндиамина, обладающие воздействием при аутоиммунных расстройствах
US7550473B2 (en) 2003-01-30 2009-06-23 Boehringer Ingelheim Pharmaceuticals, Inc. Pyrimidine derivatives useful as inhibitors of PKC-theta
US7557207B2 (en) 2004-11-24 2009-07-07 Rigel Pharmaceuticals, Inc. Spiro 2,4-pyrimidinediamine compounds and their uses
US7579344B2 (en) 2003-05-16 2009-08-25 Astrazeneca Ab Pyrimidine derivatives possessing cell-cycle inhibitors activity
WO2009122180A1 (en) * 2008-04-02 2009-10-08 Medical Research Council Pyrimidine derivatives capable of inhibiting one or more kinases
US7601714B2 (en) 2004-07-08 2009-10-13 Boehringer Ingelheim Pharmaceuticals, Inc. Pyrimidine derivatives useful as inhibitors of PKC-theta
JP2009540013A (ja) * 2006-06-15 2009-11-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ２−アニリノ−４−（複素環）アミノ−ピリミジン
US7655652B2 (en) 2004-02-03 2010-02-02 Astrazeneca Ab Imidazolo-5-yl-2-anilinopyrimidines as agents for the inhibition of cell proliferation
EP2161259A1 (de) 2008-09-03 2010-03-10 Bayer CropScience AG 4-Halogenalkylsubstituierte Diaminopyrimidine als Fungizide
EP2179991A1 (de) 2008-10-21 2010-04-28 Bayer Schering Pharma Aktiengesellschaft Sulfoximinsubstituierte Anilino-Pyrimidinderivate als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
EP2179992A1 (de) 2008-10-21 2010-04-28 Bayer Schering Pharma Aktiengesellschaft Sulfonsubstituierte Anlinopyrimidinderivative als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
EP2179993A1 (de) 2008-10-21 2010-04-28 Bayer Schering Pharma Aktiengesellschaft Sulfoxidsubstituierte Anilinopyrimidinderivative als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
US7754714B2 (en) 2004-05-18 2010-07-13 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
DE102009001438A1 (de) 2009-03-10 2010-09-16 Bayer Schering Pharma Aktiengesellschaft Carbonylamino-substituierte Anilino-Pyrimidinderivate als Tyk-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
US7799915B2 (en) * 2004-10-13 2010-09-21 Wyeth Llc Anilino-pyrimidine analogs
DE102009015070A1 (de) 2009-03-30 2010-10-14 Bayer Schering Pharma Aktiengesellschaft Aminocabonylamino-substituierte Anilino-Pyrimidinderivate als Tyk-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
WO2010141406A2 (en) 2009-06-01 2010-12-09 Osi Pharmaceuticals, Inc. Amino pyrimidine anticancer compounds
US7863286B2 (en) 2004-11-15 2011-01-04 Rigel Pharmaceuticals, Inc. Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
WO2011039344A1 (en) * 2009-10-02 2011-04-07 Boehringer Ingelheim International Gmbh Pyrimidine derivatives as protein tyrosine kinase 2 inhibitors
DE102010014426A1 (de) 2010-04-01 2011-10-06 Bayer Schering Pharma Aktiengesellschaft Verwendung neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren
DE102010014427A1 (de) 2010-04-01 2011-10-06 Bayer Schering Pharma Aktiengesellschaft Kombinationen neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren
US8044040B2 (en) 2001-06-26 2011-10-25 Bristol-Myers Squibb Company N-heterocyclic inhibitors of TNF-alpha expression
WO2012044577A1 (en) 2010-09-27 2012-04-05 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
WO2012074951A1 (en) 2010-11-29 2012-06-07 OSI Pharmaceuticals, LLC Macrocyclic kinase inhibitors
EP2242367A4 (en) * 2008-01-08 2012-07-04 Univ Pennsylvania Rel inhibitors and methods of use thereof
US8377943B2 (en) 2008-11-14 2013-02-19 Boehringer Ingelheim International Gmbh 2,4-diaminopyrimidine derivates as PTK2-inhibitors for the treatment of abnormal cell growth
WO2013139734A1 (de) 2012-03-21 2013-09-26 Bayer Intellectual Property Gmbh Verwendung von (rs)-s-cyclopropyl-s-(4-{[4-{[(1r, 2r)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluormethyl)pyrimidin-2-yl]amino}phenyl)sulfoximid zur behandlung spezifischer tumore
EP2708556A1 (en) 2012-09-12 2014-03-19 Samsung Electronics Co., Ltd Pharmaceutical composition for the use in a combination therapy for prevention or treatment of C-Met or angiogenesis factor induced diseases
WO2014106606A1 (en) * 2013-01-05 2014-07-10 F. Hoffmann-La Roche Ag Nove phenyl/pyridine series substitued by hydroxyethylamino for the treatment of cancer
WO2014173815A1 (en) 2013-04-23 2014-10-30 Bayer Pharma Aktiengesellschaft Use of (rs)-s-cyclopropyl-s-(4-{[4-{[(1r, 2r)-2-hydroxy-1-methylpropyl]oxy}-5- (trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulphoximide for the treatment of specific tumours
US8962643B2 (en) 2006-02-24 2015-02-24 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
WO2016112111A1 (en) 2015-01-08 2016-07-14 The Board Of Trustees Of The Leland Stanford Junior University Factors and cells that provide for induction of bone, bone marrow, and cartilage
WO2019157020A1 (en) 2018-02-06 2019-08-15 The Board Of Trustees Of The University Of Illinois Substituted benzothiophene analogs as selective estrogen receptor degraders
WO2020222668A1 (en) 2019-04-30 2020-11-05 Instituto de Medicina Molecular João Lobo Antunes Rank pathway inhibitors in combination with cdk inhibitors
WO2022111621A1 (en) * 2020-11-27 2022-06-02 Anrui Biomedical Technology (Guangzhou) Co., Ltd. Aminoheteroaryl kinase inhibitors
WO2023226920A1 (en) * 2022-05-27 2023-11-30 Anrui Biomedical Technology (Guangzhou) Co.,Ltd. Aminoheteroaryl kinase inhibitors
WO2024059010A1 (en) * 2022-09-13 2024-03-21 Genesis Therapeutics, Inc. Compounds for treating cancer
WO2024243485A1 (en) * 2023-05-25 2024-11-28 Odyssey Therapeutics, Inc. Cdk2 inhibitors and uses thereof
US12291529B2 (en) 2023-02-16 2025-05-06 Gasherbrum Bio, Inc. Heterocyclic GLP-1 agonists

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100874791B1 (ko) * 2001-05-29 2008-12-18 바이엘 쉐링 파마 악티엔게젤샤프트 Ｃｄｋ-억제 피리미딘, 그의 제조방법 및 약제로서의 용도
US20050282814A1 (en) * 2002-10-03 2005-12-22 Targegen, Inc. Vasculostatic agents and methods of use thereof
BR0316680A (pt) * 2002-11-28 2005-10-18 Schering Ag Pirimidinas inibidoras de chk, pdk e akt, sua produção e uso como agentes farmacêuticos
US7157455B2 (en) * 2003-02-10 2007-01-02 Hoffmann-La Roche Inc. 4-Aminopyrimidine-5-one derivatives
KR20070011458A (ko) * 2004-04-08 2007-01-24 탈자진 인코포레이티드 키나제의 벤조트리아진 억제제
US7534780B2 (en) * 2004-05-21 2009-05-19 Bayer Schering Pharma Aktiengesellschaft Estradiol prodrugs
US20050277625A1 (en) * 2004-05-21 2005-12-15 Ralf Wyrwa Estriol and estetrol prodrugs
PL382308A1 (pl) 2004-08-25 2007-08-20 Targegen, Inc. Związki heterocykliczne i sposoby stosowania
NZ555474A (en) * 2004-12-17 2010-10-29 Astrazeneca Ab 4-(4-(imidazol-4-yl) pyrimidin-2-ylamino) benzamides as CDK inhibitors
US20060247250A1 (en) * 2005-03-16 2006-11-02 Targegen, Inc. Pyrimidine inhibitors of kinases
EP1883302A4 (en) * 2005-05-03 2009-05-20 Rigel Pharmaceuticals Inc JAK KINASE HEMMER AND ITS USE
NZ563984A (en) * 2005-06-08 2011-11-25 Targegen Inc Methods and compositions for the treatment of ocular disorders
EP1741709A1 (en) * 2005-06-28 2007-01-10 Sanofi-Aventis Deutschland GmbH Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals
MX2008001428A (es) * 2005-07-30 2008-04-04 Astrazeneca Ab Compuestos de imidazolil-pirimidina para uso en el tratamiento de trastornos proliferativos.
US9018209B2 (en) * 2005-09-23 2015-04-28 Yale University Compounds and methods for the treatment of viruses and cancer
DE102005048072A1 (de) * 2005-09-24 2007-04-05 Bayer Cropscience Ag Thiazole als Fungizide
WO2007036732A1 (en) * 2005-09-30 2007-04-05 Astrazeneca Ab Imidazo [1,2-a] pyridine having anti-cell-proliferation activity
US20070110751A1 (en) * 2005-10-25 2007-05-17 Maclellan Robb Compositions and methods for reducing infarct size
CN103626742B (zh) 2005-11-01 2017-04-26 塔格根公司 激酶的联-芳基间-嘧啶抑制剂
US8133900B2 (en) * 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
US8604042B2 (en) * 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US20070149508A1 (en) * 2005-11-02 2007-06-28 Targegen, Inc. Six membered heteroaromatic inhibitors targeting resistant kinase mutations
US20070197488A1 (en) * 2005-11-29 2007-08-23 Olaf Peters Prodrugs of ERbeta-selective substances, process for their production, and pharmaceutical compositions that contain these compounds
US20070123500A1 (en) * 2005-11-29 2007-05-31 Gerd Mueller Prodrugs of ERbeta-selective substances, processes for their preparation and pharmaceutical compositions comprising these compounds
US20070135399A1 (en) * 2005-11-30 2007-06-14 Ralf Wyrwa Heteroaromatic sulphonamide prodrugs
US20070135375A1 (en) * 2005-11-30 2007-06-14 Ralf Wyrwa Sulfamoyl sulfonate prodrugs
DE102006001161A1 (de) * 2006-01-06 2007-07-12 Qiagen Gmbh Verfahren zum Nachweis von Cytosin-Methylierungen
PE20120006A1 (es) * 2006-05-15 2012-02-02 Boehringer Ingelheim Int Compuestos derivados de pirimidina como inhibidores de la quinasa aurora
TW200811169A (en) * 2006-05-26 2008-03-01 Astrazeneca Ab Chemical compounds
WO2007146977A1 (en) * 2006-06-15 2007-12-21 Boehringer Ingelheim International Gmbh 2-anilino-4-aminoalkyleneaminopyrimidines
TWI343262B (en) * 2006-09-26 2011-06-11 Schering Corp Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist
CN101535276B (zh) 2006-10-23 2013-08-28 赛福伦公司 作为ALK和c-MET抑制剂的2,4-二氨基嘧啶稠合双环衍生物
BRPI0810411B8 (pt) * 2007-04-18 2021-05-25 Pfizer Prod Inc derivados de sulfonil amida para o tratamento de crescimento celular anormal, seu sos, bem como composição farmacêutica
KR101294731B1 (ko) * 2007-06-04 2013-08-16 삼성디스플레이 주식회사 어레이 기판, 이를 갖는 표시패널 및 이의 제조방법
US20090030005A1 (en) * 2007-07-19 2009-01-29 Amgen Inc. Combinations for the treatment of cancer
MX2010011463A (es) 2008-04-16 2011-06-03 Portola Pharm Inc 2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak quinasas.
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
NZ588830A (en) * 2008-04-22 2012-11-30 Portola Pharm Inc Inhibitors of protein kinases
TW201020245A (en) * 2008-08-20 2010-06-01 Schering Corp Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
JP5644499B2 (ja) * 2008-09-01 2014-12-24 アステラス製薬株式会社 ２，４−ジアミノピリミジン化合物
US20110071158A1 (en) * 2009-03-18 2011-03-24 Boehringer Ingelheim International Gmbh New compounds
US8927547B2 (en) 2010-05-21 2015-01-06 Noviga Research Ab Pyrimidine derivatives
PT2576541T (pt) 2010-06-04 2016-07-08 Hoffmann La Roche Derivados de aminopirimidina como moduladores de lrrk2
CA2816957A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
HRP20172006T1 (hr) 2010-11-10 2018-02-09 Genentech, Inc. Derivati pirazol-aminopiridina kao lrrk2-modulatori
DK2688883T3 (en) 2011-03-24 2016-09-05 Noviga Res Ab pyrimidine
CA3094793A1 (en) 2011-11-23 2013-05-30 Portola Pharmaceuticals, Inc. Pyrazine kinase inhibitors
BR112014009717B1 (pt) * 2011-11-29 2022-06-14 Genentech, Inc Derivados de 2-(fenil ou pirid-3-il)aminopirimidina, seus usos, e composição farmacêutica
CN106458990B (zh) * 2014-04-04 2019-06-07 希洛斯医药品股份有限公司 细胞周期蛋白依赖性激酶7(cdk7)的抑制剂
CN108721307B (zh) * 2018-03-20 2021-01-15 重庆医科大学 Cdk2激酶抑制剂在制备乙型肝炎治疗药物中的应用
SMT202500389T1 (it) 2018-12-28 2025-11-10 Deciphera Pharmaceuticals Llc Inibitori di csf1r per l'uso nel trattamento di tumori tenosinoviali a cellule giganti
EP3947368B1 (en) * 2019-04-04 2025-09-03 Dana-Farber Cancer Institute, Inc. Bifunctional compounds comprising a cdk2/5 ligand, a linker and a e3 ubiquitin ligase binding degron for the treatment of cancer
CN111138417B (zh) * 2019-12-18 2021-03-23 浙江工业大学 一种三氮唑修饰的5-氟-2,4-嘧啶二胺类化合物及其应用
CN112110863A (zh) * 2020-08-27 2020-12-22 中山大学 一种磺酰氟类化合物、其制备方法以及通过其制备磺酰胺类化合物的方法
CN114105887B (zh) * 2021-09-16 2023-12-01 沈阳药科大学 一种氨基嘧啶衍生物及其制备方法和用途
CN115304550A (zh) * 2022-07-25 2022-11-08 南通大学 哌嗪苯基氨基取代的嘧啶氨基酸衍生物及制备方法与应用
CN115232076A (zh) * 2022-07-25 2022-10-25 南通大学 苯氨基取代的嘧啶氨基酸衍生物及其制备方法与应用
CN115304551A (zh) * 2022-07-25 2022-11-08 南通大学 2-((4-吗啉苯基)氨基)嘧啶氨基酸衍生物及其制备方法与应用
US20250206720A1 (en) 2023-12-08 2025-06-26 Deciphera Pharmaceuticals, Llc Solid forms of an ulk inhibitor
WO2025122952A1 (en) 2023-12-08 2025-06-12 Deciphera Pharmaceuticals, Llc Formulations of vimseltinib
WO2025231106A1 (en) 2024-05-01 2025-11-06 Deciphera Pharmaceuticals, Llc Csf-1r inhibitors and methods of use thereof
CN119707835A (zh) * 2024-11-25 2025-03-28 沈阳药科大学 2-氨基嘧啶-5-甲酰胺类化合物及用于制备治疗和/或预防癌症药物中的用途

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0224339A2 (en) * 1985-10-30 1987-06-03 Kumiai Chemical Industry Co., Ltd. Pyrimidine derivative, process for preparing same and agricultural or horticultural fungicidal composition containing same
EP0310550A1 (de) * 1987-09-28 1989-04-05 Ciba-Geigy Ag Schädlingsbekämpfungsmittel
JPH03127790A (ja) * 1989-10-11 1991-05-30 Morishita Pharmaceut Co Ltd Ｎ―（１ｈ―テトラゾール―５―イル）―２―アニリノ―５―ピリミジンカルボキシアミド類及びその合成中間体
DE4029650A1 (de) * 1990-09-19 1992-03-26 Hoechst Ag 2-anilino-pyrimidine, verfahren zu ihrer herstellung, sie enthaltene mittel und ihre verwendung als fungizide
WO1998033798A2 (en) * 1997-02-05 1998-08-06 Warner Lambert Company Pyrido[2,3-d]pyrimidines and 4-amino-pyrimidines as inhibitors of cell proliferation
WO1999050251A2 (en) * 1998-03-28 1999-10-07 Cancer Research Campaign Technology Limited Cyclin dependent kinase inhibitors
WO2000039101A1 (en) * 1998-12-24 2000-07-06 Astrazeneca Ab Pyrimidine compounds
WO2000053595A1 (en) * 1999-03-06 2000-09-14 Astrazeneca Ab Pyrimidine compounds
WO2001014375A1 (en) * 1999-08-21 2001-03-01 Astrazeneca Ab Imidazo[1,2-a]pyridine and pyrazolo[2,3-a]pyridine derivatives
WO2002004429A1 (en) * 2000-07-11 2002-01-17 Astrazeneca Ab Pyrimidine derivatives

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3947467A (en) * 1973-08-02 1976-03-30 Eli Lilly And Company 3-(5-Nitro-2-imidazolyl) pyrazoles
FR2257272B1 (https=) * 1974-01-15 1978-08-25 Pharmascience Labo
DE2413935A1 (de) * 1974-03-20 1975-10-16 Schering Ag 4-(polyalkoxy-phenyl)-2-pyrrolidone
US4193926A (en) * 1974-03-20 1980-03-18 Schering Aktiengesellschaft 4-(Polyalkoxy phenyl)-2-pyrrolidones
DE2541855A1 (de) * 1975-09-18 1977-03-31 Schering Ag 4-(polyalkoxy-phenyl)-2-pyrrolidone ii
EP0006298B1 (en) * 1978-06-15 1982-03-31 Imperial Chemical Industries Plc Anti-inflammatory 1-phenyl-2-aminoethanol derivatives, pharmaceutical compositions thereof for topical use, and processes for their manufacture
DE3374313D1 (de) * 1982-12-23 1987-12-10 Smith Kline French Lab Aminopyrimidinone derivatives as histamine h1-antagonists
DE3581570D1 (de) * 1984-06-25 1991-03-07 Ciba Geigy Ag Pyrimidinderivate wirksam als schaedlingsbekaempfungsmittel.
US4876252A (en) * 1986-01-13 1989-10-24 American Cyanamid Company 4,5,6-substituted-N-(substituted-phenyl)-2-pyrimidinamines
US4788195A (en) * 1986-01-13 1988-11-29 American Cyanamid Company 4,5,6-substituted-N-(substituted-phenyl)-2-pyrimidinamines
WO1987006576A1 (en) 1986-04-29 1987-11-05 Pfizer Inc. Calcium independent camp phosphodiesterase inhibitor antidepressant
US5128358A (en) * 1988-01-19 1992-07-07 Pfizer Inc. Aryl substituted nitrogen heterocyclic antidepressants
US4921862A (en) * 1986-05-29 1990-05-01 Syntex (U.S.A.) Inc. Carbostyril derivatives as combined thromboxane synthetase and cyclic-amp phosphodiesterase inhibitors
US4792561A (en) * 1986-05-29 1988-12-20 Syntex (U.S.A.) Inc. Carbostyril derivatives as combined thromboxane synthetase and cyclic-AMP phosphodiesterase inhibitors
CN1030415A (zh) * 1987-02-20 1989-01-18 山之内制药株式会社 饱和的杂环碳酰胺衍生物和它的制备方法
US5274002A (en) * 1987-04-14 1993-12-28 Warner-Lambert Company Trisubstituted phenyl analogs having activity for congestive heart failure
US4971959A (en) * 1987-04-14 1990-11-20 Warner-Lambert Company Trisubstituted phenyl analogs having activity for congestive heart failure
US4973690A (en) * 1988-04-12 1990-11-27 Ciba-Geigy Corporation Novel ureas
US4966622A (en) * 1988-04-12 1990-10-30 Ciba-Geigy Corporation N-phenyl-N-pyrimidin-2-ylureas
US4897396A (en) * 1988-06-03 1990-01-30 Ciba-Geigy Corporation 2-phenylamino pyrimidine derivatives and their uses as microbicides
DK0469013T3 (da) * 1989-04-17 1995-10-02 Byk Gulden Lomberg Chem Fab Hidtil ukendte arylpyridaziner, fremstilling deraf, anvendelse deraf og lægemidler indeholdende disse
US5164372A (en) * 1989-04-28 1992-11-17 Fujisawa Pharmaceutical Company, Ltd. Peptide compounds having substance p antagonism, processes for preparation thereof and pharmaceutical composition comprising the same
US5164078A (en) * 1989-12-28 1992-11-17 Chevron Research And Technology Company Process for removal of calcium from a hydrocarbon feedstock
DE4003919A1 (de) * 1990-02-09 1991-08-14 Basf Ag Heteroarylalkene, verfahren und zwischenprodukte zu ihrer herstellung und ihre verwendung
GB9007762D0 (en) 1990-04-05 1990-06-06 Beecham Group Plc Novel compounds
WO1991016892A1 (en) 1990-04-27 1991-11-14 Rorer International (Holdings), Inc. Styryl compounds which inhibit egf receptor protein tyrosine kinase
US5393788A (en) 1990-07-10 1995-02-28 Smithkline Beecham Corporation Phenylalkyl oxamides
US5124455A (en) * 1990-08-08 1992-06-23 American Home Products Corporation Oxime-carbamates and oxime-carbonates as bronchodilators and anti-inflammatory agents
NZ239946A (en) 1990-09-28 1994-09-27 Smith Kline French Lab 3-(tetrazol-5-yl)-6-(substituted phenyl)pyridine derivatives and medicaments
JPH06501941A (ja) 1990-10-16 1994-03-03 ビイク　グルデン　ロンベルク　ヒエーミツシエ　フアブリーク　ゲゼルシヤフト　ミツト　ベシユレンクテル　ハフツング アリールピリダジノン
AU9030691A (en) 1990-11-06 1992-05-26 Smithkline Beecham Corporation Imidazolidinone compounds
GB9027055D0 (en) * 1990-12-13 1991-02-06 Sandoz Ltd Organic compounds
IE71647B1 (en) 1991-01-28 1997-02-26 Rhone Poulenc Rorer Ltd Benzamide derivatives
US5698711A (en) * 1991-01-28 1997-12-16 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
US5449676A (en) 1991-04-26 1995-09-12 Byk Gulden Lomberg Chemische Fabrik Gmbh Pyridazines
PT100441A (pt) 1991-05-02 1993-09-30 Smithkline Beecham Corp Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso
EP0540165A1 (en) * 1991-10-03 1993-05-05 Zeneca Limited Alkanoic acid derivatives
DE4136921A1 (de) 1991-11-11 1993-05-13 Knoll Ag Verfahren zur trennung von 5-methyl-tetrahydrofolsaeure
US5385963A (en) * 1992-01-30 1995-01-31 Gencorp Inc. Unsaturated polyester-modified flexible copolymers for use in sheet molding compositions
US5326898A (en) * 1992-02-11 1994-07-05 Allergan, Inc. Substituted phenylethenyl compounds having retinoid-like biological activity
WO1993019748A1 (en) 1992-04-02 1993-10-14 Smithkline Beecham Corporation Compounds useful for treating inflammatory diseases and for inhibiting production of tumor necrosis factor
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
GB9212673D0 (en) * 1992-06-15 1992-07-29 Celltech Ltd Chemical compounds
GB9212693D0 (en) * 1992-06-15 1992-07-29 Celltech Ltd Chemical compounds
CZ14795A3 (en) 1992-07-28 1996-07-17 Rhone Poulenc Rorer Ltd Benzene derivative containing phenyl group bound to aryl or heteroaryl fraction through an aliphatic or hetero atom containing group, process of its preparation and pharmaceutical composition containing thereof
GB9222253D0 (en) * 1992-10-23 1992-12-09 Celltech Ltd Chemical compounds
AU673569B2 (en) 1992-12-02 1996-11-14 Pfizer Inc. Catechol diethers as selective PDE-IV inhibitors
DK0602293T3 (da) 1992-12-07 1998-02-02 Blangy Gerard De Fremgangsmåde og indretning til behandling og valorisering af affald ved omdannelse deraf til ikke-forurenende og genanvendelige materialer
KR100190730B1 (ko) 1992-12-17 1999-06-01 디. 제이. 우드, 스피겔 알렌 제이 부신피질 호르몬 유리인자(crf) 길항물질로서 치환된 피라졸
TW263495B (https=) 1992-12-23 1995-11-21 Celltech Ltd
GB9226830D0 (en) * 1992-12-23 1993-02-17 Celltech Ltd Chemical compounds
US5622977A (en) * 1992-12-23 1997-04-22 Celltech Therapeutics Limited Tri-substituted (aryl or heteroaryl) derivatives and pharmaceutical compositions containing the same
GB9304920D0 (en) 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
GB9304919D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
GB9315595D0 (en) 1993-07-28 1993-09-08 Res Inst Medicine Chem New compounds
KR100330553B1 (ko) * 1993-10-01 2002-11-27 노파르티스 아게 약물학적활성피리딘유도체및그의제조방법
WO1995009851A1 (en) 1993-10-01 1995-04-13 Ciba-Geigy Ag Pharmacologically active pyrimidineamine derivatives and processes for the preparation thereof
US5543520A (en) 1993-10-01 1996-08-06 Ciba-Geigy Corporation Pyrimidine derivatives
JPH08503971A (ja) 1993-10-01 1996-04-30 チバ−ガイギー アクチェンゲゼルシャフト ピリミジンアミン誘導体及びその調製のための方法
ATE154932T1 (de) * 1993-11-26 1997-07-15 Pfizer Isoxazolinverbindungen als entzündungshemmende mittel
GB9326173D0 (en) * 1993-12-22 1994-02-23 Celltech Ltd Chemical compounds and process
DE69433594T2 (de) * 1993-12-22 2004-08-05 Celltech R&D Ltd., Slough Trisubstituierte phenyl-derivate, verfahren zu deren herstellung und deren verwendung als phosphodiesterase (typ iv) hemmstoffe
GB9326699D0 (en) * 1993-12-22 1994-03-02 Celltech Ltd Chemical compounds
US5691376A (en) * 1994-02-17 1997-11-25 American Home Products Corporation Substituted biphenyl derivatives
US5559137A (en) 1994-05-16 1996-09-24 Smithkline Beecham Corp. Compounds
AU2265495A (en) 1994-06-06 1996-01-04 Pfizer Inc. Substituted pyrazoles having corticotropin-releasing factor (crf) antagonist activity
US5786354A (en) 1994-06-21 1998-07-28 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives and processes for their preparation
US6245774B1 (en) 1994-06-21 2001-06-12 Celltech Therapeutics Limited Tri-substituted phenyl or pyridine derivatives
GB9412573D0 (en) * 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412571D0 (en) * 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412672D0 (en) * 1994-06-23 1994-08-10 Celltech Ltd Chemical compounds
WO1996014843A2 (en) 1994-11-10 1996-05-23 Cor Therapeutics, Inc. Pharmaceutical pyrazole compositions useful as inhibitors of protein kinases
GB2301363B (en) * 1994-12-23 1998-12-30 Celltech Therapeutics Ltd Human phosphodiesterase type ivc and its production and use
US5593997A (en) * 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
CA2230896A1 (en) 1995-09-01 1997-03-13 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
US5776699A (en) 1995-09-01 1998-07-07 Allergan, Inc. Method of identifying negative hormone and/or antagonist activities
BR9610823A (pt) * 1995-10-02 1999-07-13 Hoffmann La Roche Derivados de pirimidina como antagonistas do receptor
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
GB9526245D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526246D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526243D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9608435D0 (en) * 1996-04-24 1996-06-26 Celltech Therapeutics Ltd Chemical compounds
US5785354A (en) * 1996-05-06 1998-07-28 Temtec, Inc. Self-expiring identification band
GB9619284D0 (en) * 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
GB9625184D0 (en) * 1996-12-04 1997-01-22 Celltech Therapeutics Ltd Chemical compounds
US6057329A (en) 1996-12-23 2000-05-02 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives
GB9705361D0 (en) * 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
GB9713087D0 (en) 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
HRP20080359B1 (hr) 1998-11-10 2016-01-01 Janssen Pharmaceutica N.V. PIRIMIDINI KOJI INHIBIRAJU REPLIKACIJU HIV-a
DE29912568U1 (de) 1999-07-19 2000-12-14 C.M.S. S.P.A. Uffici Commerciali, Marano Rücknahmevorrichtung
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
EP1343782B1 (en) 2000-12-21 2009-05-06 SmithKline Beecham Corporation Pyrimidineamines as angiogenesis modulators
KR100874791B1 (ko) * 2001-05-29 2008-12-18 바이엘 쉐링 파마 악티엔게젤샤프트 Ｃｄｋ-억제 피리미딘, 그의 제조방법 및 약제로서의 용도
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
EP1453516A2 (de) 2001-10-17 2004-09-08 Boehringer Ingelheim Pharma GmbH & Co.KG 5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren
ATE407678T1 (de) 2001-10-17 2008-09-15 Boehringer Ingelheim Pharma Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
CA2476281A1 (en) 2002-02-08 2003-08-14 Smithkline Beecham Corporation Pyrimidine compounds
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
WO2003095448A1 (en) 2002-05-06 2003-11-20 Bayer Pharmaceuticals Corporation Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
AR039540A1 (es) 2002-05-13 2005-02-23 Tibotec Pharm Ltd Compuestos microbicidas con contenido de pirimidina o triazina
BR0316680A (pt) * 2002-11-28 2005-10-18 Schering Ag Pirimidinas inibidoras de chk, pdk e akt, sua produção e uso como agentes farmacêuticos
DE10349423A1 (de) * 2003-10-16 2005-06-16 Schering Ag Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0224339A2 (en) * 1985-10-30 1987-06-03 Kumiai Chemical Industry Co., Ltd. Pyrimidine derivative, process for preparing same and agricultural or horticultural fungicidal composition containing same
EP0310550A1 (de) * 1987-09-28 1989-04-05 Ciba-Geigy Ag Schädlingsbekämpfungsmittel
JPH03127790A (ja) * 1989-10-11 1991-05-30 Morishita Pharmaceut Co Ltd Ｎ―（１ｈ―テトラゾール―５―イル）―２―アニリノ―５―ピリミジンカルボキシアミド類及びその合成中間体
DE4029650A1 (de) * 1990-09-19 1992-03-26 Hoechst Ag 2-anilino-pyrimidine, verfahren zu ihrer herstellung, sie enthaltene mittel und ihre verwendung als fungizide
WO1998033798A2 (en) * 1997-02-05 1998-08-06 Warner Lambert Company Pyrido[2,3-d]pyrimidines and 4-amino-pyrimidines as inhibitors of cell proliferation
WO1999050251A2 (en) * 1998-03-28 1999-10-07 Cancer Research Campaign Technology Limited Cyclin dependent kinase inhibitors
WO2000039101A1 (en) * 1998-12-24 2000-07-06 Astrazeneca Ab Pyrimidine compounds
WO2000053595A1 (en) * 1999-03-06 2000-09-14 Astrazeneca Ab Pyrimidine compounds
WO2001014375A1 (en) * 1999-08-21 2001-03-01 Astrazeneca Ab Imidazo[1,2-a]pyridine and pyrazolo[2,3-a]pyridine derivatives
WO2002004429A1 (en) * 2000-07-11 2002-01-17 Astrazeneca Ab Pyrimidine derivatives

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
"Ambinter Exploratory Library", AMBINTER, F-75016 PARIS *
"Oak Samples Product List", 8 October 2001, OAK SAMPLES LTD., 03680 KIEV-142, UKRAINE *
BOSCHELLI D H ET AL: "SYNTHESIS AND TYROSINE KINASE INHIBITORY ACTIVITY OF A SERIES OF 2-AMINO-8-H-PYRIDOÄ2,3-DÜPYRIMIDINES: IDENTIFICATION OF POTENT, SELECTIVE PLATELET-DERIVED GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 41, no. 22, 1998, pages 4365 - 4377, XP002191993, ISSN: 0022-2623 *
DATABASE CHEMCATS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 21 January 2002 (2002-01-21), XP002210161, retrieved from STN *
DATABASE CHEMCATS [online] CHEMICAL ABSTRACTS SERVICES, COLUMBUS, OHIO, US; XP002210162, retrieved from STN *
DATABASE CROSSFIRE BEILSTEIN [online] Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE; XP002210163, Database accession no. BRN 249340, 265505 *
DING, SHENG ET AL: "A Combinatorial Scaffold Approach toward Kinase-Directed Heterocycle Libraries", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2002), 124(8), 1594-1596, XP002210160 *
NAITO, I. ET AL., CHEM. PHARM. BULL., vol. 6, 1958, pages 338 - 341 *

Cited By (178)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8044040B2 (en) 2001-06-26 2011-10-25 Bristol-Myers Squibb Company N-heterocyclic inhibitors of TNF-alpha expression
EP2332924A1 (de) * 2001-10-17 2011-06-15 Boehringer Ingelheim Pharma GmbH & Co. KG Pyrimidinderivate, Arzneimittel enthaltend diese Verbindungen, deren Verwendung und Verfahren zu ihrer Herstellung
EP1438053A1 (de) 2001-10-17 2004-07-21 Boehringer Ingelheim Pharma GmbH & Co.KG Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung
WO2003032994A3 (de) * 2001-10-17 2003-06-12 Boehringer Ingelheim Pharma 5-substituierte 4-amino-2-phenylamino-pyrimidinderivate und ihre verwendung als beta-amyloid modulatoren
US8420630B2 (en) 2001-10-17 2013-04-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pyrimidine derivatives
EP2090571A1 (de) * 2001-10-17 2009-08-19 Boehringer Ingelheim Pharma GmbH & Co. KG Pyrimidinderivate, Arzneimittel enthaltend diese Verbindungen, deren Verwendung und Verfahren zu ihrer Herstellung
US7709480B2 (en) 2001-10-17 2010-05-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pyrimidine derivatives
US7173028B2 (en) 2001-10-17 2007-02-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pyrimidine derivatives
US7166599B2 (en) 2001-10-17 2007-01-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Trisubstituted pyrimidines
WO2003055489A1 (en) * 2001-12-21 2003-07-10 Bayer Pharmaceuticals Corporation 2,4-diamino-pyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
US7329672B2 (en) 2002-02-01 2008-02-12 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US7642351B2 (en) 2002-02-01 2010-01-05 Rogel Pharmaceuticals, Inc. 2,4-Pyrimidinediamine compounds and their uses
US10682350B2 (en) 2002-02-01 2020-06-16 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US9346765B2 (en) 2002-02-01 2016-05-24 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US7906644B2 (en) 2002-02-01 2011-03-15 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US10709703B2 (en) 2002-02-01 2020-07-14 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US7435814B2 (en) 2002-02-01 2008-10-14 Rigel Pharmaceuticals, Inc. 2,4-Pyrimidinediamine compounds and their uses
US9416112B2 (en) 2002-02-01 2016-08-16 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US7329671B2 (en) 2002-02-01 2008-02-12 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US7820819B2 (en) 2002-02-01 2010-10-26 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
EP1471915A4 (en) * 2002-02-01 2006-02-15 Rigel Pharmaceuticals Inc 2,4-pyrimidine-dinamine compounds and their use
US7803939B2 (en) 2002-02-01 2010-09-28 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US9018204B1 (en) 2002-02-01 2015-04-28 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US7550460B2 (en) 2002-02-01 2009-06-23 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US7485724B2 (en) 2002-02-01 2009-02-03 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US8835430B2 (en) 2002-02-01 2014-09-16 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US9913842B2 (en) 2002-02-01 2018-03-13 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US7498435B2 (en) 2002-02-01 2009-03-03 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US7655797B2 (en) 2002-02-01 2010-02-02 Rigel Pharmaceuticals, Inc. Intermediates for making 2,4-pyrimidinediamine compounds
US7332484B2 (en) 2002-02-01 2008-02-19 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US7589200B2 (en) 2002-02-01 2009-09-15 Rigel Pharmaceuticals, Inc. 5-Fluoro-4N-phenyl-4-pyrimidineamine compounds
US8334296B2 (en) 2002-02-01 2012-12-18 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US7557210B2 (en) 2002-02-01 2009-07-07 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US7485638B2 (en) 2002-03-09 2009-02-03 Astrazeneca Ab Pyrimidine compounds
US7465728B2 (en) 2002-03-09 2008-12-16 Astrazeneca Ab Derivatives of 4-(imidazol-5-yl)-2-(4-sulfoanilino)pyrimidine with CDK inhibitory activity
US7446105B2 (en) 2002-03-09 2008-11-04 Astrazeneca Ab Pyrimidine compounds
US7442697B2 (en) 2002-03-09 2008-10-28 Astrazeneca Ab 4-imidazolyl substituted pyrimidine derivatives with CDK inhibitory activity
US7812029B1 (en) 2002-07-29 2010-10-12 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
US7517886B2 (en) 2002-07-29 2009-04-14 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
US8158621B2 (en) 2002-07-29 2012-04-17 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
US7825116B2 (en) 2002-07-29 2010-11-02 Rigel Pharmaceuticals, Inc. N2, N4-bis-aryl-5-fluoro-2,4-pyrimidinediamines
US7351712B2 (en) 2002-12-20 2008-04-01 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
NL1025071C2 (nl) * 2002-12-20 2004-12-30 Pfizer Prod Inc Verbindingen voor de behandeling van abnormale celgroei.
US7674796B2 (en) 2002-12-20 2010-03-09 Pfizer Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
US7741336B2 (en) 2002-12-20 2010-06-22 Pfizer Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
WO2004056786A3 (en) * 2002-12-20 2004-10-21 Pfizer Prod Inc Pyrimidine derivates for the treatment of abnormal cell growth
US7109337B2 (en) 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
US7109335B2 (en) 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
JP2006515298A (ja) * 2002-12-20 2006-05-25 ファイザー・プロダクツ・インク 異常な細胞増殖を治療するためのピリミジン誘導体
US7550473B2 (en) 2003-01-30 2009-06-23 Boehringer Ingelheim Pharmaceuticals, Inc. Pyrimidine derivatives useful as inhibitors of PKC-theta
US7427626B2 (en) 2003-05-16 2008-09-23 Astrazeneca Ab 2-Anilino-4-(imidazol-5-yl)-pyrimidine derivatives and their use as cdk (cdk2) inhibitors
US7579344B2 (en) 2003-05-16 2009-08-25 Astrazeneca Ab Pyrimidine derivatives possessing cell-cycle inhibitors activity
US8178671B2 (en) 2003-07-30 2012-05-15 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds
WO2005016893A3 (en) * 2003-07-30 2005-06-09 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
US7452879B2 (en) 2003-07-30 2008-11-18 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
KR101201603B1 (ko) 2003-07-30 2012-11-14 리겔 파마슈티칼스, 인크. 자가면역 질환의 치료 또는 예방에 사용하기 위한2,4-피리미딘디아민 화합물
RU2356901C2 (ru) * 2003-07-30 2009-05-27 Райджел Фармасьютикалз, Инк. Соединения 2, 4-пиримидиндиамина, обладающие воздействием при аутоиммунных расстройствах
US7582648B2 (en) 2003-07-30 2009-09-01 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
JP2007500722A (ja) * 2003-07-30 2007-01-18 リゲル ファーマシューティカルズ，インコーポレイティド ２，４−ピリミジンジアミン化合物による自己免疫疾患の治療または予防方法
JP4886511B2 (ja) * 2003-07-30 2012-02-29 ライジェル ファーマシューティカルズ， インコーポレイテッド ２，４−ピリミジンジアミン化合物による自己免疫疾患の治療または予防方法
US7560466B2 (en) 2003-07-30 2009-07-14 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
CN1849318B (zh) * 2003-07-30 2011-10-12 里格尔药品股份有限公司 用2,4-嘧啶二胺化合物预防和治疗自体免疫疾病的方法
US9751893B2 (en) 2003-07-30 2017-09-05 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
JP2007501793A (ja) * 2003-08-07 2007-02-01 リゲル ファーマシューティカルズ，インコーポレイティド 抗増殖剤としての２，４−ピリミジンジアミン化合物および使用
US8507510B2 (en) 2003-10-16 2013-08-13 Bayer Intellectual Property Gmbh Sulfoximine-substituted pyrimidines as CDK- and/or VEGF inhibitors, their production and use as pharmaceutical agents
DE10349423A1 (de) * 2003-10-16 2005-06-16 Schering Ag Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
WO2005037800A1 (de) * 2003-10-16 2005-04-28 Schering Aktiengesellschaft Sulfoximinsubstituierte pyrimidine als cdk- und/oder vegf-inhibitoren, deren herstellung und verwendung als arzneimittel
CN1867553B (zh) * 2003-10-16 2011-06-08 舍林股份公司 作为cdk 和/或vegf 抑制剂的氨基亚砜取代的嘧啶化合物、其制备方法以及作为药物的用途
JP2007508354A (ja) * 2003-10-16 2007-04-05 シエーリング アクチエンゲゼルシャフト Ｃｄｋ−及び／又はｖｅｇｆインヒビターとしてのスルホキシミン−置換ピリミジン類、それらの生成及び医薬としての使用
US7338958B2 (en) 2003-10-16 2008-03-04 Schering Ag Sulfoximine-substituted pyrimidines as CDK-and/or VEGF inhibitors, their production and use as pharmaceutical agents
AU2004281960B2 (en) * 2003-10-16 2010-07-01 Bayer Intellectual Property Gmbh Sulfoximine-substituted pyrimidines for use as CDK and/or VEGF inhibitors, the production thereof and their use as drugs
NO337290B1 (no) * 2003-10-16 2016-02-29 Bayer Ip Gmbh Sulfoksiminsubstituerte pyrimidiner for anvendelse som CDK og /eller VEGF-inhibitorer, fremstilling derav og deres anvendelse som legemidler
JP2007514775A (ja) * 2003-12-19 2007-06-07 ライジェル ファーマシューティカルズ， インコーポレイテッド １−（２，４−ピリミジンジアミノ）−２−シクロペンタンカルボキサイミド合成中間体の立体異性体および立体異性体混合物
WO2005063722A1 (en) * 2003-12-19 2005-07-14 Rigel Pharmaceuticals, Inc. Stereoisomers and stereoisomeric mixtures of 1-(2,4-pyrimidinediamino)-2-cyclopentanecarboxamide synthetic intermediates
US7511137B2 (en) 2003-12-19 2009-03-31 Rigel Pharmaceuticals, Inc. Stereoisomers and stereoisomeric mixtures of 1-(2,4-pyrimidinediamino)-2-cyclopentanecarboxamide synthetic intermediates
US7655652B2 (en) 2004-02-03 2010-02-02 Astrazeneca Ab Imidazolo-5-yl-2-anilinopyrimidines as agents for the inhibition of cell proliferation
US7208499B2 (en) 2004-05-14 2007-04-24 Pfizer Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
US7145008B2 (en) 2004-05-14 2006-12-05 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
WO2005111024A1 (en) * 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
US7235562B2 (en) 2004-05-14 2007-06-26 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
US7754714B2 (en) 2004-05-18 2010-07-13 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
US7868013B2 (en) 2004-05-18 2011-01-11 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
JP4812763B2 (ja) * 2004-05-18 2011-11-09 ライジェル ファーマシューティカルズ， インコーポレイテッド シクロアルキル置換ピリミジンジアミン化合物およびそれらの用途
US7858633B2 (en) 2004-05-18 2010-12-28 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
US8410093B2 (en) 2004-05-18 2013-04-02 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
US9725419B2 (en) 2004-05-18 2017-08-08 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
US7601714B2 (en) 2004-07-08 2009-10-13 Boehringer Ingelheim Pharmaceuticals, Inc. Pyrimidine derivatives useful as inhibitors of PKC-theta
WO2006034872A1 (de) * 2004-09-29 2006-04-06 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-anilinopyrimidine als zellzyklus -kinase oder rezeptortyrosin-kinase inhibitoren, deren herstellung und verwendung als arzneimittel
US7799915B2 (en) * 2004-10-13 2010-09-21 Wyeth Llc Anilino-pyrimidine analogs
US8030483B2 (en) 2004-11-15 2011-10-04 Rigel Pharmaceuticals, Inc. Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
US7863286B2 (en) 2004-11-15 2011-01-04 Rigel Pharmaceuticals, Inc. Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
US8044054B2 (en) 2004-11-15 2011-10-25 Rigel Pharmaceuticals, Inc. Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
US8101627B2 (en) 2004-11-15 2012-01-24 Rigel Pharmaceuticals, Inc. Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
US7851480B2 (en) 2004-11-24 2010-12-14 Rigel Pharmaceuticals, Inc. Spiro 2,4-pyrimidinediamine compounds and their uses
US7557207B2 (en) 2004-11-24 2009-07-07 Rigel Pharmaceuticals, Inc. Spiro 2,4-pyrimidinediamine compounds and their uses
US7563892B1 (en) 2005-01-19 2009-07-21 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4 pyrimidinediamine compounds and their uses
US9266912B2 (en) 2005-01-19 2016-02-23 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US9532998B2 (en) 2005-01-19 2017-01-03 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US7449458B2 (en) 2005-01-19 2008-11-11 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US10577381B2 (en) 2005-01-19 2020-03-03 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US7538108B2 (en) 2005-01-19 2009-05-26 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
WO2006077428A1 (en) 2005-01-21 2006-07-27 Astex Therapeutics Limited Pharmaceutical compounds
WO2006087230A1 (de) * 2005-02-17 2006-08-24 Schering Aktiengesellschaft Verwendung von cdk ii inhibitoren zur fertilitätskontrolle
JP2008535807A (ja) * 2005-03-23 2008-09-04 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト Ｃｄｋ−及び／又はｖｅｇｆインヒビターとしてのｎ−アリール−スルホキシミン−置換されたピリミジン類、それらの生成及び医薬剤としての使用
WO2006099974A1 (en) * 2005-03-23 2006-09-28 Bayer Schering Pharma Aktiengesellschaft N-aryl-sulfoximine-substituted pyrimidines as cdk- and/or vegf inhibitors, their production and use as pharmaceutical agents
EP1705177A1 (en) * 2005-03-23 2006-09-27 Schering Aktiengesellschaft N-aryl-sulfoximine-substituted pyrimidines as CDK- and/or VEGF inhibitors, their production and use as pharmaceutical agents
US7456191B2 (en) 2005-03-23 2008-11-25 Schering Ag N-Aryl-sulfoximine-substituted pyrimidines as CDK-and/or VEGF inhibitors, their production and use as pharmaceutical agents
WO2006133426A3 (en) * 2005-06-08 2007-11-08 Rigel Pharmaceuticals Inc Compositions and methods for inhibition of the jak pathway
AU2006254840B2 (en) * 2005-06-08 2012-08-02 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US8415365B2 (en) 2005-06-08 2013-04-09 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US9593082B2 (en) 2005-06-08 2017-03-14 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
RU2485106C2 (ru) * 2005-06-08 2013-06-20 Райджел Фамэсьютикэлз, Инк. Соединения, проявляющие активность в отношении jak-киназы (варианты), способ лечения заболеваний, опосредованных jak-киназой, способ ингибирования активности jak-киназы (варианты), фармацевтическая композиция на основе указанных соединений
US8399472B2 (en) 2005-06-08 2013-03-19 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US9248190B2 (en) 2005-06-08 2016-02-02 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US11198689B2 (en) 2005-06-08 2021-12-14 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US9732073B2 (en) 2005-06-08 2017-08-15 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
NO341966B1 (no) * 2005-06-08 2018-03-05 Riegel Pharmaceuticals Inc Sammensetninger og fremgangsmåter for inhibering av JAK-reaksjonsveien.
CN105348203B (zh) * 2005-06-08 2018-09-18 里格尔药品股份有限公司 抑制jak途径的组合物和方法
US10421752B2 (en) 2005-06-08 2019-09-24 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US11827628B2 (en) 2005-06-08 2023-11-28 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US7491732B2 (en) 2005-06-08 2009-02-17 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
WO2007003596A1 (de) * 2005-07-01 2007-01-11 Boehringer Ingelheim International Gmbh 2,4-diamino-pyrimidine als aurora inhibitoren
EA016358B1 (ru) * 2005-07-01 2012-04-30 Бёрингер Ингельхайм Интернациональ Гмбх 2,4-диаминопиримидины как ингибиторы aurora
WO2007060110A1 (en) * 2005-11-22 2007-05-31 F. Hoffmann-La Roche Ag 4-aminopyrimidine-5-thione-derivatives for the treatment of cancer
EP1803723A1 (de) 2006-01-03 2007-07-04 Bayer Schering Pharma Aktiengesellschaft (2,4,9-triaza-1(2,4)-pyrimidina-3(1,3)-benzenacyclononaphan-3^4-yl)-sulfoximid derivate als selektive inhibitoren der aurora kinase zur behandlung von krebs
WO2007089445A2 (en) 2006-01-27 2007-08-09 Amgen Inc. Ang2 and vegf inhibitor combinations
US8962643B2 (en) 2006-02-24 2015-02-24 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US11667611B2 (en) 2006-02-24 2023-06-06 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
JP2009540013A (ja) * 2006-06-15 2009-11-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ２−アニリノ−４−（複素環）アミノ−ピリミジン
EP1878726A1 (en) * 2006-07-12 2008-01-16 Bayer Schering Pharma Aktiengesellschaft Substituted sulphoximines as Tie2 inhibitors and salts thereof, pharmaceutical compositions comprising the same, methods of preparing the same and uses of the same
WO2008006560A1 (en) * 2006-07-12 2008-01-17 Bayer Schering Pharma Aktiengesellschaft Substituted sulphoximines as tie2 inhibitors and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
US8003655B2 (en) 2006-07-12 2011-08-23 Bayer Schering Pharma Ag Substituted sulphoximines as TIE2 inhibitors and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
WO2008044045A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
WO2008044041A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
WO2008079907A1 (en) * 2006-12-20 2008-07-03 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
WO2008074515A1 (de) * 2006-12-20 2008-06-26 Bayer Schering Pharma Aktiengesellschaft Neuartige hetaryl-phenylendiamin-pyrimidine als proteinkinaseinhibitoren zur behandlung von krebs
EP1939185A1 (de) * 2006-12-20 2008-07-02 Bayer Schering Pharma Aktiengesellschaft Neuartige Hetaryl-Phenylendiamin-Pyrimidine als Proteinkinaseinhibitoren zur Behandlung von Krebs
WO2008077885A2 (en) 2006-12-22 2008-07-03 Boehringer Ingelheim International Gmbh 2- [(phenylamino) -pyrimidin-4ylamin0] -cyclopentane carboxamide derivatives and related compounds as inhibitors of kinases of the cell cycle for the treatment of cancer
DE102007010801A1 (de) 2007-03-02 2008-09-04 Bayer Cropscience Ag Diaminopyrimidine als Fungizide
CN101621927A (zh) * 2007-03-02 2010-01-06 拜尔农作物科学股份公司 用作杀菌剂的二氨基嘧啶
EA015174B1 (ru) * 2007-03-02 2011-06-30 Байер Кропсайенс Аг Диаминопиримидины в качестве фунгицидов
WO2008107096A1 (de) * 2007-03-02 2008-09-12 Bayer Cropscience Ag Diaminopyrimidine als fungizide
WO2008140421A3 (en) * 2007-05-15 2009-04-30 S Bio Pte Ltd Heterocycloalkyl substituted pyrimidine derivatives
US8609730B2 (en) 2008-01-08 2013-12-17 The Trustees Of The University Of Pennsylvania Rel inhibitors and methods of use thereof
EP2242367A4 (en) * 2008-01-08 2012-07-04 Univ Pennsylvania Rel inhibitors and methods of use thereof
WO2009122180A1 (en) * 2008-04-02 2009-10-08 Medical Research Council Pyrimidine derivatives capable of inhibiting one or more kinases
EP2161259A1 (de) 2008-09-03 2010-03-10 Bayer CropScience AG 4-Halogenalkylsubstituierte Diaminopyrimidine als Fungizide
WO2010025871A1 (de) * 2008-09-03 2010-03-11 Bayer Cropscience Ag 4-halogenalkylsubstituierte diaminopyrimidine als fungizide
EP2179991A1 (de) 2008-10-21 2010-04-28 Bayer Schering Pharma Aktiengesellschaft Sulfoximinsubstituierte Anilino-Pyrimidinderivate als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
EP2179992A1 (de) 2008-10-21 2010-04-28 Bayer Schering Pharma Aktiengesellschaft Sulfonsubstituierte Anlinopyrimidinderivative als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
EP2179993A1 (de) 2008-10-21 2010-04-28 Bayer Schering Pharma Aktiengesellschaft Sulfoxidsubstituierte Anilinopyrimidinderivative als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
US8377943B2 (en) 2008-11-14 2013-02-19 Boehringer Ingelheim International Gmbh 2,4-diaminopyrimidine derivates as PTK2-inhibitors for the treatment of abnormal cell growth
DE102009001438A1 (de) 2009-03-10 2010-09-16 Bayer Schering Pharma Aktiengesellschaft Carbonylamino-substituierte Anilino-Pyrimidinderivate als Tyk-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
DE102009015070A1 (de) 2009-03-30 2010-10-14 Bayer Schering Pharma Aktiengesellschaft Aminocabonylamino-substituierte Anilino-Pyrimidinderivate als Tyk-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
WO2010141406A2 (en) 2009-06-01 2010-12-09 Osi Pharmaceuticals, Inc. Amino pyrimidine anticancer compounds
US8399433B2 (en) 2009-06-01 2013-03-19 OSI Pharmaceuticals, LLC Amino pyrimidine anticancer compounds
WO2011039344A1 (en) * 2009-10-02 2011-04-07 Boehringer Ingelheim International Gmbh Pyrimidine derivatives as protein tyrosine kinase 2 inhibitors
US8466155B2 (en) 2009-10-02 2013-06-18 Boehringer Ingelheim International Gmbh Pyrimidines
DE102010014426A1 (de) 2010-04-01 2011-10-06 Bayer Schering Pharma Aktiengesellschaft Verwendung neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren
DE102010014427A1 (de) 2010-04-01 2011-10-06 Bayer Schering Pharma Aktiengesellschaft Kombinationen neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren
WO2012044577A1 (en) 2010-09-27 2012-04-05 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
WO2012074951A1 (en) 2010-11-29 2012-06-07 OSI Pharmaceuticals, LLC Macrocyclic kinase inhibitors
WO2013139734A1 (de) 2012-03-21 2013-09-26 Bayer Intellectual Property Gmbh Verwendung von (rs)-s-cyclopropyl-s-(4-{[4-{[(1r, 2r)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluormethyl)pyrimidin-2-yl]amino}phenyl)sulfoximid zur behandlung spezifischer tumore
EP2708556A1 (en) 2012-09-12 2014-03-19 Samsung Electronics Co., Ltd Pharmaceutical composition for the use in a combination therapy for prevention or treatment of C-Met or angiogenesis factor induced diseases
WO2014106606A1 (en) * 2013-01-05 2014-07-10 F. Hoffmann-La Roche Ag Nove phenyl/pyridine series substitued by hydroxyethylamino for the treatment of cancer
WO2014173815A1 (en) 2013-04-23 2014-10-30 Bayer Pharma Aktiengesellschaft Use of (rs)-s-cyclopropyl-s-(4-{[4-{[(1r, 2r)-2-hydroxy-1-methylpropyl]oxy}-5- (trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulphoximide for the treatment of specific tumours
WO2016112111A1 (en) 2015-01-08 2016-07-14 The Board Of Trustees Of The Leland Stanford Junior University Factors and cells that provide for induction of bone, bone marrow, and cartilage
WO2019157020A1 (en) 2018-02-06 2019-08-15 The Board Of Trustees Of The University Of Illinois Substituted benzothiophene analogs as selective estrogen receptor degraders
WO2020222668A1 (en) 2019-04-30 2020-11-05 Instituto de Medicina Molecular João Lobo Antunes Rank pathway inhibitors in combination with cdk inhibitors
WO2023093769A1 (en) * 2020-11-27 2023-06-01 Anrui Biomedical Technology (Guangzhou) Co.,Ltd. Aminoheteroaryl kinase inhibitors
WO2022111621A1 (en) * 2020-11-27 2022-06-02 Anrui Biomedical Technology (Guangzhou) Co., Ltd. Aminoheteroaryl kinase inhibitors
EP4251613A4 (en) * 2020-11-27 2024-11-20 Allorion Therapeutics Inc. AMINOHETEROARYL KINASE INHIBITORS
AU2021385745C1 (en) * 2020-11-27 2025-02-20 Allorion Therapeutics Inc Aminoheteroaryl kinase inhibitors
AU2021385745A9 (en) * 2020-11-27 2025-03-27 Allorion Therapeutics Inc Aminoheteroaryl kinase inhibitors
WO2023226920A1 (en) * 2022-05-27 2023-11-30 Anrui Biomedical Technology (Guangzhou) Co.,Ltd. Aminoheteroaryl kinase inhibitors
WO2024059010A1 (en) * 2022-09-13 2024-03-21 Genesis Therapeutics, Inc. Compounds for treating cancer
US12291529B2 (en) 2023-02-16 2025-05-06 Gasherbrum Bio, Inc. Heterocyclic GLP-1 agonists
WO2024243485A1 (en) * 2023-05-25 2024-11-28 Odyssey Therapeutics, Inc. Cdk2 inhibitors and uses thereof

Also Published As

Publication number Publication date
US20080039447A1 (en) 2008-02-14
ES2320204T3 (es) 2009-05-20
US20040102630A1 (en) 2004-05-27
US7235561B2 (en) 2007-06-26
PL367130A1 (en) 2005-02-21
US7598260B2 (en) 2009-10-06
KR20040030645A (ko) 2004-04-09
NZ529654A (en) 2005-12-23
AR036035A1 (es) 2004-08-04
HRP20031081A2 (en) 2005-10-31
US7291624B2 (en) 2007-11-06
NO327129B1 (no) 2009-04-27
ATE420077T1 (de) 2009-01-15
JP2004535414A (ja) 2004-11-25
DE50213202D1 (de) 2009-02-26
MEP13408A (en) 2010-06-10
KR100874791B1 (ko) 2008-12-18
NO20035298D0 (no) 2003-11-28
CN1633419A (zh) 2005-06-29
RU2330024C2 (ru) 2008-07-27
IL159120A0 (en) 2004-05-12
MXPA03010810A (es) 2004-03-22
CO5540316A2 (es) 2005-07-29
BR0209774A (pt) 2004-06-01
RS94703A (sr) 2007-02-05
JP4291135B2 (ja) 2009-07-08
AU2002312933B2 (en) 2007-12-06
CA2449118A1 (en) 2002-12-05
RU2003136080A (ru) 2005-05-20
EP1392662A1 (de) 2004-03-03
CN100480242C (zh) 2009-04-22
EP1392662B1 (de) 2009-01-07
US20040224966A1 (en) 2004-11-11

Similar Documents

Publication Publication Date Title
EP1392662A1 (de) Cdk inhibitorische pyrimidine, deren herstellung und verwendung als arzneimittel
DE10148618B4 (de) Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
EP1483260A1 (de) Cdk inhibitorische 2-heteroaryl-pyrimidine, deren herstellung und verwendung als arzneimittel
EP1530574B1 (de) Makrozyklische pyrimidine, deren herstellung und verwendung als arzneimittel
EP1387840B1 (de) 3,5-diamino-1,2,4-triazole als kinase inhibitoren
EP1673352B1 (de) Sulfoximinsubstituierte pyrimidine als cdk- und/oder vegf-inhitoren, deren herstellung und verwendung als arzneimittel
DE60316013T2 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
WO2002044148A2 (de) Aryl-substituierte indirubinderivate, deren herstellung und verwendung
EP1598343A1 (de) 2-Arylaminopyrimidine als PLK Inhibitoren
WO2003032997A1 (de) Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung
DE102005062742A1 (de) Sulfoximin substituierte Pyrimidine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel
EP1794134A1 (de) Substituierte 2-anilinopyrimidine als zellzyklus -kinase oder rezeptortyrosin-kinase inhibitoren, deren herstellung und verwendung als arzneimittel
WO2002034717A1 (de) Schwefelhaltige indirubinderivate, deren herstellung und verwendung
DE10219294A1 (de) Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
DE10129028A1 (de) Lösliche Cdk-inhibitorische Indirubinderivate
DE10114138C2 (de) Cdk-inhibitorische Indirubinderivate mit erhöhter Löslichkeit
EP0645390A1 (de) Trisubstituierte Pyrimido/5,4-d/-pyrimidine zur Modulation der Multidrugresistenz, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
WO2002092079A1 (de) Verwendung selektiver indirubinderivate als vegf-r inhibitoren
DE10148617A1 (de) Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
DE10212098A1 (de) CDK inhibitorische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
DE10127581A1 (de) CDK inhibitorische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
DE10255984A1 (de) CDK inhibitorische 2-Heteroaryl-Pyrimidine, deren Herstellung und Verwendung als Arnzeimittel
DE10212100A1 (de) CDK inhibitorische 2-Heteroaryl-Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
DE102004049622A1 (de) Subtituierte 2-Anilinopyrimidine als Zellzyklus-kinase oder Rezeptortyrosin-kinase Inhibitoren, deren Herstellung und Verwendung als Arzneimittel

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-947/03

Country of ref document: YU

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002738100

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 529654

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/010810

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 159120

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2003500067

Country of ref document: JP

Ref document number: 1020037015597

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2449118

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 200309824

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 1-2003-501345

Country of ref document: PH

Ref document number: 02240/DELNP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: P20031081A

Country of ref document: HR

WWE Wipo information: entry into national phase

Ref document number: 2002312933

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002814886X

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2002738100

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 529654

Country of ref document: NZ